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ABSTRACT 
   
Parkinson’s disease, the most prevalent movement disorder of the central nervous 
system, is a chronic condition that affects more than 1000,000 U.S. residents and about 3% 
of the population over the age of 65. The characteristic symptoms include tremors, 
bradykinesia, rigidity and impaired postural stability. Current therapy based on 
augmentation or replacement of dopamine is designed to improve patients’ motor 
performance but often leads to levodopa-induced complications, such as dyskinesia and 
motor fluctuation. With the disease progress, clinicians must closely monitor patients’ 
progress in order to identify any complications or decline in motor function as soon as 
possible in PD management. Unfortunately, current clinical assessment for Parkinson’s is 
subjective and mostly influenced by brief observations during patient visits.  Thus 
improvement or decline in patients’ motor function in between visits is extremely 
difficult to assess. This may hamper clinicians while making informed decisions about 
the course of therapy for Parkinson’s patients and could negatively impact clinical care. 
In this study we explored new approaches for PD assessment that aim to provide 
home-based PD assessment and monitoring. By extending the disease assessment to 
home, the healthcare burden on patients and their family can be reduced, and the disease 
progress can be more closely monitored by physicians. To achieve these aims, two novel 
approaches have been designed, developed and validated. The first approach is a 
questionnaire based self-evaluation metric, which estimate the PD severity through using 
self-evaluation score on pre-designed questions. Based on the results of the first approach, 
a smart phone based approach was invented. The approach takes advantage of the mobile 
computing technology and clinical decision support approach to evaluate the motor 
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performance of patient daily activity and provide the longitudinal disease assessment and 
monitoring. Both approaches have been validated on recruited PD patients at the 
movement disorder program of Barrow Neurological Clinic (BNC) at St Joseph’s 
Hospital and Medical Center. The results of validation tests showed favorable accuracy 
on detecting and assessing critical symptoms of PD, and shed light on promising future of 
implementing mobile platform based PD evaluation and monitoring tools to facilitate PD 
management. 
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CHAPTER 1 
INTRODUCTION AND BACKGROUND 
 
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder, which 
influences 0.3 percent of the U.S population, and up to 3 percent of population over 65 
ages in the world (1, 2). As the most common movement disorder, PD can cause 
significant disability and decreased quality of life(3). The course of the disease is chronic 
and progressive, and may be complicated by a wide range of motor and non-motor 
features(4). When PD becomes clinically overt, tremor, rigidity, bradykinesia, and 
postural instability become the cardinal signs of the disease(5). Although PD remains an 
incurable progressive disease, modern treatment can substantially improves quality of life 
and functional capability. Current therapy based on augmentation or replacement of 
dopamine is successful in improving patients’ motor performance in early stages of 
disease(6). However, the management of advanced PD becomes more complex. For PD 
patients who receive levodopa treatment for more than 5 years, the vast majority of them 
experience motor complications in the form of motor fluctuation and dyskinesia. These 
levodopa-induced complications constitute a substantial problem in the long-term 
management of PD. Current medical approaches to manage the motor complications 
include manipulation of the medication dosage and frequency, according to the 
assessment of disease status change and progress of symptoms. However, since PD 
evaluation is mostly conducted in clinical setting during patients’ visits, the decline and 
improvement of symptoms between the clinic visits can only be tracked through 
subjective reporting by patients to physicians. This methodological weakness, to some 
extent, prohibits physicians to make more informed decisions from a closer monitoring 
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on disease progress, and limits the information for predicting long-term disease 
progression from research perspective. Moreover, frequent clinic visits also increase the 
clinical burden of PD management, as well as the physical and economic burden for PD 
patients’ family. To fill the information gap between two clinic visits and to reduce the 
patients’ physical burden as well as the care of burden, we conducted an initiative study 
to explore a tentative home based PD assessment and monitoring approach, by taking 
advantage of mobile computing, machine learning and advanced sensor technologies. 
This approach aims to provide a quantitative and objective evaluation approach to 
measure Parkinson’s disease status in home based environment, which could be used as 
an extension to current clinical setting based evaluation in long term PD management. In 
this study, two approaches have been explored, including initial methodology design, 
development, validation, clinical test results, and feasibility discussion. The first 
approach, which is based on patient self evaluation questionnaires, is described in 
CHAPTER 2. With the preliminary results of the self evaluation questionnaires, we 
further designed a smart phone based PD evaluation approach in CHAPTER 3, which 
takes advantage of the 3D accelerometer integrated in smart phone to provide Parkinson’s 
disease motoring and evaluation. 
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1. Parkinson’s Disease  
1.1. Epidemiology 
1.1.1. Prevalence and Incidence 
Parkinson’s disease (PD) is the most common movement disorder besides 
essential tremor, and the second most common neurodegenerative disease(3). Early onset 
of sporadic PD is rare, with about 4% of patients developing clinical signs of the disease 
before an age of 50 years(7). The incidence of the disease rises steeply with age, from 
17.4 in 100,000 persons between 50 and 59 years old to 93.1 in 100,000 persons between 
70 and 79 years old, and increase to 3% ~ 5% in people 85 years older, while a lifetime 
risk of developing the disease is 1.5% (8-10). The median age of onset is 60 years and the 
mean duration of the disease from starting diagnosis to death is 15 years, with a mortality 
ratio of 2 to 1(11). Although PD has been found in all ethnic groups, it has geographical 
difference. It is found more common in developed countries..  
1.1.2. Risk factors 
Although etiology of PD still remains unclear, current studies suggest that a 
combination of age, genetic and non-genetic factors are involved together in PD 
etiology(12). Similar toother neurodegenerative diseases, aging is the major risk factor. 
Although 10% of people with PD are younger than 45 years of age, the PD incidence rate 
in subjects more than 85 years old was about 14 times that observed in subjects aged 56 
to 65 years(13). Evidence from prospective long term studies also suggests that higher 
age at motor onset is the major denominator of more rapid motor progression in PD (14, 
15). Other than age, gender has also been found a risk of developing PD. It has been 
reported males, particularly in the older age groups, have a higher incidence rate, around 
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1.5 times more likely than women to develop Parkinson’s disease(16). However, in 
younger PD patients less than 60 years at onset, several studies found no differences in 
incidence of PD between men and women(17). The environmental factors and living 
style have also been reported to be related to PD development. It has been found that 
smoking cigarette, drinking coffee and tea can lower the risk of incidence of PD, but 
consistently exposure to pesticides increases the risk (18, 19). Although smoking, tea and 
coffee have been shown to influence the onset of PD, they appear not to impact the rate 
of motor progression in overt PD (20-22). 
Family history is also an important risk factor that closely associated with the risk 
of PD. The patients who have family members affected by PD are at 3 to 4 fold increased 
risk to develop the disease comparing to others in general population (11, 23). Due to this 
aggregation of PD within families and pedigrees, a genetic cause of the disease has been 
hypothesized for several decades. From the genetic studies in the recent decades, several 
gene loci have been found to be associated with the Parkinsonism. Some of them were 
found to be associated with autosomal-dominantly(24-27) or recessively(28-30) inherited 
parkinsonism, while others such as the most recently identified leucine-rick repeat kinase 
2 (LRRK2) mutations appear to cause parkinsonism resembling sporadic PD with respect 
to both clinical and demographical features (31). The discovery of these genetic 
mutations and the increased understanding of dysfunction of their aberrantly encoded 
proteins have provided important and novel insights into the molecular pathogenesis of 
the disease. There is now compelling evidence that impairment of the ubiqutine-
proteasome system, mitochondrial dysfunction and decreased oxidative stress tolerance 
are key pathological mechanisms in PD pathogenesis(32, 33). However, the exact 
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mechanisms are not completely understood, and monogenetic causes only account for a 
small proportion (<10%) of all PD cases, while the vast majority of PD cases appear to be 
sporadic. In these sporadic PD cases, occupational, lifestyle and environmental factors, 
possibly interacting with each other and with susceptibility genes, may play a part. 
1.2. Clinical Features and Symptoms 
The initial presentation of PD is with onset of a rest tremor, impairment of 
dexterity or, less commonly, with a slight dragging of one foot. The onset is gradual and 
the earliest symptoms might be unnoticed or misinterpreted. When PD becomes clinically 
overt, tremor, rigidity, bradykinesia, and postural instability are considered to be the 
cardinal signs of the disease(5). The course of the disease is chronic and progressive, and 
may be complicated by a wide range of motor and non-motor features. 
1.2.1 Cardinal Signs 
Rest tremor (4 ~ 6 Hz frequency) is the most common cardinal sign at motor 
onset. Roughly around 30% of individuals do not have rest tremor at onset, (34), and25% 
of patients with PD never develop tremor. Rest tremor usually appears maximal when the 
limb is at rest and disappears with voluntary movement and sleep, and is worsened by 
excitement, anxiety, or apprehension. It affects to a greater extent the most distal part of 
the limb and at onset typically appears in only a single arm or leg, and then becomes 
bilateral later. The rest tremor is usually a pronation-supination tremor that is described 
as "pill-rolling"; a term used to describe a circular movement of the tips of the thumb and 
the index finger when brought together. Such term was given due to the similarity of the 
movement in PD patients with the former pharmaceutical technique of manually making 
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pills(35). As opposed to essential tremor, rest tremor in PD is not improved with alcohol 
intake(34). 
Rigidity is characterized by increased resistance to passive stretch of skeletal 
muscles, and is frequently seen with PD. Rigidity may be associated with joint pain; such 
pain being a frequent initial manifestation of the disease(34). When PD patients’ limbs 
are passively moved by others, a "cogwheel rigidity" is commonly observed(34). 
Cogwheel-like refers to the ratchety jerks by which the articulation is moved as opposed 
to the normal fluid movement: when a muscle is externally tried to be moved, it get resist 
at first but with enough force it is partially moved until it get resist again, and only with 
further force it will be moved(34, 36). The combination of tremor and increased muscle 
tone is considered to be at the origin of cogwheel rigidity. 
Bradykinesia, referring to slowness of movements with difficulties in initiating 
and maintaining motions, is the most characteristic clinical feature of PD, and is 
associated with difficulties along the whole course of the movement process, from 
planning, initiating to finally executing of a movement(34).
 
The performance of 
sequential and simultaneous movements is also hindered(34).
 
Bradykinesia is the most 
disabling symptom in the early stages of the disease(36). Initial manifestations of 
bradykinesia are problems when performing daily life tasks requiring fine motor control 
such as writing, sewing or getting dressed(34). Clinical evaluation is based on similar 
tasks such as alternating movements between both hands or feet(36). Bradykinesia is not 
equal for all movements or times. It is modified by the activity or emotional state of the 
subject to the point that some patients barely able to walk may be capable of riding a 
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bicycle(34). Generally patients have less difficulty when external cues are provided (34, 
37). 
Postural instability, although is not typical at disease onset, becomes a common 
complication of advanced PD in late disease stage. Postural instability usually causes 
impaired balance and frequent falls, and also leads to bone fractures(34). Instability is 
often absent in the initial stages, especially for younger people(36). Up to 40% of the 
patients may experience falls and around 10% may have falls weekly, with number of 
falls being related to the severity of PD. It is produced by a failure of postural reflexes, 
along with other disease related factors such as orthostatic hypotension or cognitive and 
sensory changes(34). 
1.2.2. Motor Symptoms 
Besides the four cardinal signs of PD, the individuals with PD also show one or 
more other motor symptoms in the course of PD. The motor symptoms can be generally 
grouped to gait and posture disturbance and speech and swallowing related disturbance. 
Shuffling of gait, freezing of gait, dystonia and festination are usually the typical gait and 
posture disturbance appearing in PD patients (38). Among these gait and posture 
symptoms, the freezing of gait (FOG) is one common symptom affecting advanced PD 
patients in their daily livings. FOG describes patients’ difficulty moving their feet and 
may become apparent as start hesitation, turn hesitation, destination hesitation, or halting 
when walking (39). FOG often occurs suddenly, and the frequency and severity of FOG 
increases with the progression of PD. Dystonia is a disorder occasionally found in 
Parkinson’s disease, which causes uncontrollable and painful spasms in parts of body. 
Dystonia is very uncommon in untreated patients and is more frequently seen as a 
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complication of PD treatments(12). Festinating gait (FSG) is a unique disturbance of 
locomotion associated with Parkinsonism. FSG is observed in PD as rapid and small 
steps, done in an attempt to keep the center of gravity in between the feet while the trunk 
leans forward involuntarily and shift the center of gravity forward(20). Other than gait 
and posture disturbance, the speech and swallowing disturbances include voice disorders 
and mask-like face expression (14).  
In the very majority of patients with PD, the initial motor symptoms are localized 
to the upper extremities(40), then spread to the other ipsilateral limb within one to three 
years, and affect the contralateral limbs in three to eight years(41). The asymmetrical 
pattern, however, usually persists during the course of the disease, even in advanced 
stages(42). Severity of bradykinesia, rigidity, and gait and balance progress similarly, 
while tremor severity appears to be rather stable over time, possibly indicating different 
underlying pathophysiological processes. 
1.2.3. Non-motor Symptoms 
Although the symptoms of PD are typically observed as motor disturbance, the 
vast majority of PD patients also experience non-motor problems during the course of 
their disease. In a cross-sectional clinic-based study of 99 PD patients, only 12% of them 
have not experienced any non-motor problems after seven years of disease duration(43). 
The non-motor symptoms usually include sleep disturbances, autonomic dysfunction, 
olfactory deficits, sensory complaints, and in particular a wide range of neuropsychiatric 
problems including cognitive impairment and dementia. These non-motor symptoms may 
also lead to substantially decreasedfunctioning and quality of life of patients(44).  
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The cognitive impairment and dementia are two major non-motor symptoms that 
attract much more attention in PD management. Cognitive impairment can occur in the 
initial stages of the disease and sometimes even prior to diagnosis, and is progressive 
with duration of the disease (8, 34). Patients with cognitive impairment usually find that 
they have difficulties in planning and carrying through tasks, paying attention, word-
finding, learning and memorizing information(45). The severe cognitive impairment can 
lead to dementia, which is a more severe decline in multiple mental abilities, including 
but not limited to memory. The dementia can interfere with daily living and  lead to 
trouble at home or at work, or in social situations, and results in the patient’s inability to 
live independently in severe condition (46). 
1.2.4. Motor Complications 
The course of PD is frequently complicated by variations in motor response. 
Motor complications comprise dyskinesia, which are episodes of abnormal involuntary 
movements involving head, trunk, limbs, and motor fluctuations, describing a transient 
decline in motor performance(47). The presence and development of dyskinesia and 
motor fluctuations are associated with each other and both features increase in frequency 
and severity with the duration of disease(31, 48). Around 1/3
rd
 of patients develop motor 
complications within four to six years after disease onset(49), and dyskinesia and “end of 
dose failure” is experienced by almost all patients past 15 years of disease duration(15).  
Motor fluctuations in PD are induced by taking levodopa, which is an effective 
medication in controlling PD symptoms and used by almost all patients with Parkinson’s 
disease. The motor fluctuation mainly represents in two patterns: “Wearing-off” 
fluctuations and “On-off” fluctuations. Patients with “Wearing-off” pattern develop a 
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predictable worsening at the end of the current dose because of the short-duration benefit 
after a given dose of levodopa. “On-off” fluctuations are characterized by sudden and 
unpredictable shifts between on and off states. This produces off states in a random 
fashion such that patients cannot predict when the next will occur. These episodes vary in 
time, are unrelated to medication dose, and occur suddenly. Most patients with “On-off” 
pattern also experience “Wearing-off”. 
1.3. Diagnosis 
There are two approaches usually used to diagnose Parkinson’s disease in clinical 
practice: 1) functional neuroimaging and 2) clinical criteria. Although functional 
neuroimaging is useful in the differential diagnosis of PD and more or less frequently 
used in everyday practice, the common diagnosis of PD is still conducted at the clinic 
visits by using clinical criteria to provide a diagnosis of probable PD.  A diagnosis of PD 
requires the presence of at least two of the following cardinal signs: rest tremor, rigidity, 
bradykinesia, asymmetrical onset, and the absence of atypical features such as severe 
postural instability, frequent falls, autonomic, pyramidal or cerebellar features, eye 
movement disorders, or lack of response to dopaminergic treatments(50).  
Parkinson’s disease is by far the most common cause of bradykinesia(51). among 
the four cardinal signs, the bradykinesia is the most important diagnositic criteria, without 
which the diagnosis of Parkinson’s disease cannot be made (38). Although individuals 
with monosymptomatic rest tremor who have abnormalities of striatal dopamine on 
functional imaging exist. Bradykinesia can display in rigid facial expression, as well as 
the slow ability to express emotions. Speaking might also be slow, quiet, and lack in 
rhythm and melody. The rapid repetitive finger tapping of the index finger on the thumb 
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for about 20s on each hand is a commonly used clinical test. Bradykinesia of the lower 
limbs can be assessed by fast foot tapping and walking.  
The rest tremor (within 4~6 Hz), which might be the only evident when the part 
of body is truly at rest, is another important characteristic associated with Parkinson’s 
disease diagnosis. Young patients (<40 years of age) frequently present with tremor, 
which is more severe onlegsand noted when lying or sitting, whereas older patients (>70 
years of age) might have tremor on jaw, chin, lips, and tongue(38). Although the presence 
of rest tremor is helpful for the diagnosis of Parkinson’s disease, a similar tremor can 
occur in some cases of dystonic and atypical tremor syndromes(52). Besides rest tremor, 
essential re-emergent postural tremor as well as an action tremor can also be seen in 
Parkinson’s disease(53). 
Flexion of the limbs and trunk is also a characteristic of Parkinson’s disease. The 
flexion of limbs and trunk can represent in a variety of ways on different individuals. 
Some patients have transient fixed hand posturing after completing a motor task. Some 
patients have motor impatience with a difficulty finding a comfortable position to rest 
their limbs, and few have striking mirror movements. Absent arm swing, a mild flexion 
of arm at elbow, can be one of the earliest clues to diagnosis. 
Besides the above clinical signs of PD, other well-known signs of PD include 
late-onset postural instability, decreased olfaction, and micrographia. In diagnosis of PD, 
patients must also respond to an adequate therapeutic challenge of levodopa or a 
dopamine agonist. For detail description of symptoms and signs associated with 
Parkinson’s disease, please refer to results of related studies (51, 54). 
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1.4. Treatment 
Although Parkinson’s disease is still an incurable progressive disease, treatments 
can substantially improve the quality of life and motor function of capacity. Treatments 
of PD mainly focus on symptom management, and include motor symptom and non-
motor symptom management. Symptomatic therapy for Parkinson’s disease should be 
initiated at the onset of functional impairment. In early-stage disease management, the 
treatment with monoamine oxidase-B (MAO-B) inhibitors, amantadine, or 
anticholinergics may modestly improve mild symptoms. However, most patients need 
levodopa or a dopamine agonist when there is functional impairment. Levodopa is the 
most effective pharmacologic agent for Parkinson’s disease and remains the primary 
treatment for symptomatic patients (6, 9). Levodopa is particularly effective at 
controlling bradykinesia and rigidity(6); However, speech, postural reflex, and gait 
disturbance are less likely to respond. In general, for early-stage PD, a dopamine agonist 
is initiated for patients with mild disease with onset at a younger age, whereas levodopa 
is initiated for older patients with severe motor symptoms.  
The late-stage Parkinson’s disease includes patients already received 
carbidopa/levodopa treatments who have developed motor complications. After five 
years of treatments with levodopa, about 40% patients develop to motor fluctuation(1). 
Patients may experience a “wearing-off” and “on-off” effects in motor complications. 
These motor complications can be treated by adding a dopamine agonist, MAO-B 
inhibitor, or catechol O-methyltransferase (COMT) inhibitor (9, 55). Dopamine agonists 
have demonstrated the function to significantly reduce “off” time, improve motor 
impairment and disability, and reduce the need for levodopa(32). The COMT inhibitors 
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also show the ability to decrease the degradation of levodopa and extend its half-life, thus 
relieve the end-of-dose wearing-off effect and reducing “off” time(56).  
However, with the progress of PD to late-stage, the pharmacologic intervention 
may hard to effectively improve motor function and reduce motor fluctuations. When PD 
develops into this stage, surgical treatment becomes the last therapeutic option to 
improve the motor functions. Deep brain stimulation (DBS) of the subthalamic nucleus 
has demonstrated the effect to improve motor function and reduces motor fluctuations, 
dyskinesia, and antiparkinsonian medication use. Unilateral pallidotomy is another 
surgery treatment for PD, which is an effective symptomatic adjunct to levodopa and can 
treat motor complications. However, the unilateral pallidotomy is used less often because 
it causes destructive lesions(57).  
2. Current PD management strategies 
As described in Parkinson’s disease treatment part, the primary disease 
management on PD is through the pharmaceutical therapy to control the symptoms and 
improve the motor function. Current therapy based on augmentation or replacement of 
dopamine is successful in improving patients’ motor performance in early stage disease. 
However, the management of advanced PD is complex. For PD patients who receive 
levodopa treatment for more than 5 years, the vast majority of them experience motor 
complications in the form of motor fluctuation and dyskinesia. These levodopa-induced 
complications constitute a substantial problem in the long-term management of PD. 
Current medical approaches to these motor complications include manipulation of the 
medication dosage and frequency, according to assessment of disease status change and 
progress of symptoms. Therefore, in order to optimize the outcome of PD management 
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and make informed decision on medication plan, physicians need to accurately assess the 
PD status from the represented symptoms and also estimate the disease progress. 
2.1. Disease Assessment Tools 
Due to lack of in vivo biomarkers and the current limitations of functional 
neuroimaging methods as surrogate markers of disease progression in PD(33), clinical 
assessment using established clinical rating scale remains the gold standard in charting 
the course of the disease. Because the manifestations of PD are complicated, and include 
motor symptoms to non-motor symptoms, and the influence of PD is diverse and 
different for each individual, various clinical assessment tools have been used for 
evaluating various aspects of Parkinson’s disease, including motor and non-motor 
severity and disability in patients with PD. Although many of them have not been 
sufficiently evaluated for reliability,  some of them have been validated and used widely 
in clinical practice by clinical professionals, such as UPDRS (Unified Parkinson’s disease 
Rating Scale)(58) and Hoehn and Yahr scale(59). Other than the disease severity 
assessment, some other evaluation scales are primarily used as patient self-reporting from 
the influence of PD on quality of life and social-economic perspectives, including PDQ39 
scale and MCSI scale (60, 61). To provide a through coverage on influence of PD in 
patients’ quality of life, the UPDRS scale is usually accompanied by additional measures 
focusing on other aspects of Parkinson’s disease and their influence on patients’ life, such 
as the Beck Depression Inventory (BDI), Fatigue Severity scale, Care Burden scale, 
Sleep scale, Cognitive scale, and etc(21, 61-63). 
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2.1.1. UPDRS 
In current Parkinson’s disease assessment, the Unified Parkinson’s Disease Rating 
Scale (UPDRS) is the most widely used primary clinical rating scales for PD evaluation, 
which was introduced in 1987 by an international group of movement disorders 
specialists(64). The UPDRS was designed to follow the longitudinal course of the disease 
and has been shown to be both reliable and valid to provide a comprehensive but efficient 
and flexible measurement to evaluate PD-related disability and impairment (24). The 
maximum total score of UPDRS is 132 points. These 132 points are composed of 4 parts, 
each of which focuses on one dimension of PD evaluation (Part I, Mentation, Behavior 
and Mood; Part II, Activities of Daily Living; Part III, Motor; Part IV, Complications). 
Despite its strengths, the UPDRS was revised to adapt to recent scientific advances, 
particularly to better capture the wide spectrum of non-motor problems experience by 
patients with PD. In these four parts, Part I and Part II of UPDRS can be answered by 
patients via self-evaluation. However, Part III Motor and Part IV Complications, the 
substantial two parts to evaluate PD symptoms severity and patients’ disability, can only 
be rated by a clinician professional in a clinic setting. In addition, the rating of the 
UPDRS heavily relies on raters’ subjective assessment, and has limited sensitivity to 
detect small change in disease progression. The rating of Part III and Part IV have 
become a regular routine in PD patients’ visits, and charted as a standard evaluation part 
in movement disorder program, to provide longitudinal information on the disease 
progress. In this study, we also used UPDRS scale as gold standard to evaluate PD 
severity, which was rated by movement disorder experts. 
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2.1.2. Hoehn & Yahr  
The Hoehn & Yahr scale was devised in 1967 and is another main scale used in 
PD(59). It measures the stage of the disease by including both impairment and disability 
of movements, balance, and gait. The scale was initially allocating 6 stages from 0 (no 
signs of disease) to 5 (wheelchair bound or bedridden unless assisted), and later stages 
1.5 and 2.5 have been added(65). In stage 1 the disease is confined to one side of the 
body (unilateral). In stage 2, the disease is bilateral but there is no problem with balance. 
In stage 3, postural instability becomes an issue. In stage 4 there is severe disability but 
the patient is still able to walk or stand. In stage 5, the patient is wheelchair bound or 
bedridden unless aided. However, non-motor features are not captured by this scale.  
2.1.3. PDQ39 
Other than the PD assessment scales rated by clinicians, another noteworthy scale, 
the Parkinson Disease Questionnaire (PDQ39), is a self-evaluation scale commonly used 
for PD patients’ self assessment. PDQ39 is composed of 39 questions from 8 dimensions 
(Mobility, Activities of daily living, Emotional well being, Stigma, Social support, 
Cognitive impairment, Communication, Bodily discomfort), which could provide general 
information about patients’ feeling and disease impact on their lives (60). Although 
PDQ39 has shown its value for measuring quality of life of Parkinson’s disease patients, 
it is limited in providing diagnostic information for physicians’ clinical decision making 
(66, 67). 
2.2. Socioeconomic effect 
Since PD is chronic and progressive, and is currently still an incurable disease, 
this disease places a substantial burden on patients, their families and carers, as well as on 
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society as a whole. PD can severely affect the health-related quality of life (HR-QOL) of 
both patients and their carers, and also induce high economic cost.  
Over the course of the disease, the HR-QOL of patients is affected by factors such 
as depression, motor complications, education and surgery, with the change of PD 
progress. The motor complications, including motor fluctuation and dyskinesia, are the 
primary factor to result in deterioration of quality of life. Several studies have found that 
the motor fluctuations and levodopa-induced dyskinesia can significantly worsen patient 
HR-QOL(54, 68, 69). The depression is another major detrimental factor on HR-QOL, 
associated with sleep disturbance, cognitive decline, occurrence of falls(70), and is one of 
the most common psychiatric disorders in PD(52).  
The economic outcomes associated with PD are of particular importance not only 
to patients, but also to their families and the society(11). The economic costs of PD are 
mainly contributed by cost of care burden, which are particularly high for patients in 
advanced stages of the disease and those with motor complications(71). The economic 
and health burden of PD also result in increasing healthcare costs and major reduction in 
the HR-QOL of both patients and their families. The total annual cost of the PD was 
estimated to be 13,800 Euros per individual (72). Due to the progressive nature of PD, 
costs increase with disease severity. The economic costs of PD are significant associated 
with PD severity, with costs increasing as the disease progresses and doubling from 
Hoehn and Yahr (H&Y) stage I to V(19). In H&Y stage of V, the direct annual costs 
were estimated to be nearly 30,000 Euros(19). The direct costs include medical (drugs, 
physician visits etc) and non-medical services (special care, transport, equipment). The 
direct costs of PD account for the major part of economic burden of the disease, 
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particularly in early stages of PD, and increase substantially with clinical progression of 
symptoms(73). The indirect costs can include changes in worker productivity, absence 
from work and decreased earning ability. They also include certain intangible costs, such 
as pain, suffering and reduced HR-QOL. The largest components of indirect costs are the 
hours required for informal caring and the earnings lost by both patients and their 
families. With more advanced stage of the disease, the fraction of indirect costs increase, 
approximately 25% after 5 years and 80% after 9 years, because many patients become 
unable to work(25). For patients with motor fluctuations, the mean costs are three times 
higher than those without motor fluctuation, and cost doubling with each H&Y stage(11).  
2.3. Challenges 
Although life expectancy and control of motor symptoms and tremor have 
improved with new treatments for Parkinson’s disease, motor complications and 
cognitive impairment in advanced disease still face important unmet therapeutic needs. 
The challenges can be divided from disease assessment and therapeutic treatment 
challenges. In terms of therapeutic challenge, the control of cognitive impairment and 
postural instability, are still important unmet therapeutic needs.  Furthermore, no 
neuroprotective treatment can arrest the underlying disease progress, and dopaminergic 
therapy is far from perfect in controlling motor disability (38). Since the goal and 
application of this study mainly aim to resolve the disease assessment challenges, we will 
mainly focus on these challenges in this part. 
As the disease progresses, motor disability and non motor problems have to be 
managed efficiently. To manage motor complications, the physician is required to modify 
the medication plan according to disease progression and appearance of new symptoms.  
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Although the current most widely used PD state assessment method, UPDRS, has been 
approved its validity and reliability in assessing PD progress, it can only be applied in a 
clinic setting under the supervision of a trained clinical observer(24). Therefore, in order 
to capture disease status change, PD patients have to repeatedly visit a clinic in person 
during long-term PD management, which is time consuming, economically burdensome, 
and brings extra care burden for patients with motor disability(34). In addition, current 
PD assessment is mostly conducted via brief observation by a clinical professional during 
a patient visit. The assessment is based on the patient’s performance at a specific time 
during the visit, not on a comprehensive assessment based on the comparative 
performance of a patient over an interval of time. In long term management, most clinical 
trials assesses the UPDRS scores at baseline and at 3 months interval, precluding 
detection of change on a weekly or monthly basis(62). Thus, the improvement or decline 
of disease status is hard to capture by clinicians during the period between two visits. 
This prevents clinicians from making the most informed decision about the course of 
therapy for Parkinson’s patients and could negatively impact clinical care.   
Another deficiency in current PD management is that PD disease assessment in a 
clinic setting is not able to effectively track and evaluate motor fluctuation, which 
requires continuous assessment of PD motor-related symptoms over a period of time. 
Motor fluctuation is one significant medical therapy-induced complication, which is 
marked by On-Off status. For patients using levodopa, a widely used medication to 
control Parkinson’s disease symptoms, the time efficacy of the medication (On-time) 
gradually decreases, as a result of which the PD symptoms come back earlier (Off time). 
To overcome the decrease of On-time while using this medication, increased levodopa 
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dosage is one solution used in early PD disease management. However, the increase of 
levodopa dosage also induces peak-dose dyskinesia, which appears as restless movement 
of a patient. Once motor fluctuations appear, therapeutic treatment should be 
individualized to retain optimal control of the symptoms based on accurate assessment of 
each patient’s levodopa cycle and responses to drugs. Because the on-off-on cycle refers 
to the several hour period after taking the medication, the change of motor performance 
with medication effect declining and peak-dose dyskinesia are hard to observe on an 
outpatient basis. In current PD management, due to lack of effective monitoring and 
evaluation tools that could track motor performance change over time, clinicians can only 
roughly estimate patient motor fluctuation by asking patients when they took their 
medication. This difficulty prevents clinicians from making an optimal medication plan 
based on patient motor fluctuation. 
3. Prospective Home-based PD Assessment 
Considering the limitation of current PD assessment approaches, the home-based 
PD assessment is a potential solution to fill the information gap by extending the clinical 
based PD evaluation to patients’ daily livings. Although many self-evaluation scales for 
PD exist in current PD management, such as PDQ 39, most of them aim to provide 
information about quality of living and are not related to clinical assessment. So it is 
hardly to use current available approaches to assess PD severity and progress for 
physicians’ decision making and longitudinal disease tracking. In this study we will 
explore the new approaches for PD assessment in home-based environment. Two novel 
approaches have been designed and developed in this study, and the preliminary testing 
and validation have been performed on PD patients. The first approach is a self-
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evaluation scale based approach, which estimates the PD severity by using the patients’ 
self-evaluation answers on pre-designed questions. Based on the result of the first 
approach, the second approach is more advanced, which takes advantage of the mobile 
computing technology and clinical decision support approach to collect the PD related 
patients’ motion data in their daily life and provide the disease assessment and 
monitoring for physicians in long term disease management. Both approaches have been 
validated on recruited patients with diagnosed Parkinson’s disease at the movement 
disorder program of Barrow Neurological Clinic (BNC) at St Joseph’s Hospital and 
Medical Center. Based on the initial result and validation tests, the feasibility of applying 
these approaches in future PD management has been also analyzed and discussed in this 
study.  
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CHAPTER 2 
HOME BASED PD SELF EVALUATION METRIC APPROACH 
 
1. Introduction 
As discussed in Disease Assessment Tools section in INTRODUCTION and 
BACKGROUND part, the current PD evaluation methods are either clinical setting based 
rating scales, such as UPDRS, which requires subjective rating from clinical 
professionals, or self-evaluation scales, such as PDQ39, which mainly focuses on quality 
of life but not too much on disease assessment.  Neither of these two kinds of scales is 
suitable for home based patient self-evaluation on PD. To resolve the above limitations of 
current PD assessment approaches and thus extend the PD evaluation to home based 
setting, the first part of this study developed a simple PD self-evaluation metric, which is 
designed to provide quantitative and objective evaluation for patients based on their 
motor performance in daily activities. With this self-evaluation metric, the association 
between the rating score of this metric and the disease status was then studied in order to 
build the predicative models to identify critical PD features and estimate severity of PD. 
Considering that the UPDRS is the standard clinical evaluation measurement in clinical 
practice, this metric was validated by comparing with UPDRS rating on the same patients. 
The accuracies of these predictive models were further verified in cross-validation, to 
compare with ground truth, the experts’ opinion. The validation results proved that this 
self-evaluation metric could effectively differentiate the performance of patients with 
different motor symptoms.  The validation and the accuracy of predictive models 
demonstrated that this metric can provide objective, quantitative, and meaningful 
information for clinical assessment of PD motor related disability, and can be easily 
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implemented in a home-based computer monitoring system and e-health applications for 
PD assessment. 
2. Method 
2.1. Development of Self-evaluation scale 
In collaboration with Muhammad Ali Parkinson Center (MAPC) at St Joseph’s 
Hospital and Medical Center, the initial PD self-evaluation scale was drafted based on Dr 
Lieberman’s long term clinical practice and study. Based on his practice in evaluating 
Parkinson’s disease patients’ motor related problems, several particular observations 
which are not typically adopted widely in PD evaluation are included in Dr Lieberman’s 
evaluation protocol. These particular observations include standing on one foot, tandem 
walking, and turning 360 degree. Based on these observations from Dr Lieberman’s 
experience, plus two quantitative measurements walking speed and stride length, this PD 
self-evaluation metric is composed of five evaluation questions. Because this self-
evaluation metric aims to be applied in a non-clinical environment by patients themselves 
or care givers, who do not have professional training and knowledge in PD. Therefore, 
the answer for each evaluation question is designed to be as objective as possible. So that 
the rater can easily select which category the patient should fall in based on the objective 
observation, without involving subjective decision making. Similar as part III (Motor 
examination) of UPDRS scale, the rating score for each evaluation question is from 0 to 4 
points. The metric includes total 5 questions, each of which require patients to complete a 
simple motor task to evaluate the motor related performance on either stability or walking. 
Different from UPDRS scale, which assesses the PD from patients’ social, cognitive and 
motor abilities, this self-evaluation metric only focus on assessing the motor ability of PD, 
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and the rating of each evaluation question is designed to be more quantitative and 
objective than UPDRS.  This metric aims to provide approach for patient to easily 
compete the rating only with simple counting and calculation, and without any PD 
professional knowledge and training. The detail definition of the scale is listed in Table 1. 
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Table 1 
The self-evaluation scale for home-based PD evaluation 
Scale item Description Rating 
Standing on one 
leg 
Evaluation for standing on right and left leg 
separately. For each leg, the score is from 0~4.  
0: Can stand stably on one leg without assistance; 
1: Can stand on one leg without assistance, but 
with a little bit shaking; 
2: Need one hand assistance to stand on one leg; 
3: Need two hands assistance to stand on one leg;  
4: Cannot stand on one leg even with assistance;  
The total score for two legs are from 0~8.   
Integer 
points: 
0, 1, 2, 3, 
4 
Turning 360 
degrees 
Evaluation for turning from left to right, and right 
to left separately. For each direction, the score is 
from 0~4. 
0: Need less than 4 steps to turn 360 degrees; 
1: Need 4~8 steps to turn 360 degrees; 
2: Need more than 8 steps to turn 360 degrees; 
3: Need assistance to complete the turning;  
4: Cannot complete the turning even with 
assistance;  
The total score for two directions turning are from 
0~8. 
Integer 
points: 
0, 1, 2, 3, 
4 
Tandem walking Evaluation for tandem walking. 
0: Can walk with tandem step stably without out 
any assistance; 
1: Can walk with tandem step without any 
assistance, but with a little bit shaking; 
2: Need one hand assistance to walk with tandem 
step; 
3: Need two hands assistance to walk with tandem 
step; 
4: Cannot walk with tandem step even with 
assistance. 
Integer 
points: 
0, 1, 2, 3, 
4 
Step length The average length (feet/step) of each step, 
calculated from number of steps taken to walk 25 
feet. 
Decimal: 
Feet 
Stride velocity The average walking speed (feet/second), 
calculated from time taken to walk 25 feet. 
Decimal: 
Feet /s 
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2.2. Experiments Design and Data Collection 
To validate the scale and build the predicative models to estimate PD status, 204 
patients diagnosed with PD were recruited to participate in this study. The participants 
were selected from regular outpatients at movement disorder program at Barrow 
Neurological Clinic (BNC). The outpatients who received PD assessment using UPDRS 
scale in their regular clinic visits were invited in this study. The participants were first 
given introduction of this metric before their clinic visit appointments. The self 
evaluation using this metric were completed by patient themselves or care givers at any 
time before their visits, and the rating result were collected during the visits. Then in their 
regular clinic visits, their disease statuses were evaluated by movement disorder experts 
at MAPC using the UPDRS scale. The UPDRS scores rated by clinical experts were used 
to validate this proposed metric and served as ground truth in building predictive models. 
Since this self-evaluation metric mainly focuses on assessing the stability and walking 
disabilities, therefore, not the full set of UPDRS scores, but only part of UPDRS scores, 
which are related to stability and working, were collected in this study. The collected 
UPDRS scores in this study are listed in Table 2. The participants’ self evaluation results 
and their UPDRS based clinical assessment were associated together for validating and 
building predicative models. Because the disease progress and status of PD are closely 
associated with the patient’s age and disease duration, the age and disease duration were 
also collected in this study for including patient demographic and general disease 
characteristics information.  
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Table 2 
Subset of UPDRS score collected in this study 
Data field Description 
Midline motor activity 
score. 
From 0~24. The summary score of 6 questions 
related to motor impairment from subset of UPDRS 
part III. 
Balance difficulty As reported on UPDRS part II. 0: no difficulty with 
balance. 1: difficulty with balance. 
Dyskinesia As reported on UPDRS part IV. 0: no dyskinesia. 
1: dyskinesia.  
Freezing of gait (FOG) Freezing when walking. UPDRS Score from 0~4 
points.  
0,1: no FOG.  2~4: FOG  
Gait difficulty Gait difficulty. UPDRS Score from 0~4 points. 
0, 1: no gait difficulty. 2~4: gait difficulty 
Postural stability Response to sudden, strong posterior displacement 
produced by pull on shoulders, while patient erect 
with eyes open and feet slightly apart. Patient is 
prepared. Score from 0~4 points. 
 
2.3. Validation 
With the collected patient self-evaluation rating and physicians’ assessments 
using UPDRS score, the proposed self-evaluation metric was validated in t-test to 
compare the ratings of the self-evaluation scale between patients with and without 
specific motor disabilities. Four motor disabilities, including gait difficulty, freezing of 
gait, dyskinesia and postural instability, are used to divide the 204 participants into four 
pair of comparing groups, as described in Table 3. The self evaluation scores were then 
compared between the patients who have and do not have the specific disability in each 
pair of comparison group through the student T-test, using SAS
®
 9.1 software package. 
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Table 3 
Comparing groups of patients, divided based on motor disabilities. 
 # Patients Having # Patients Not having Total 
G1: Gait difficulty 74 130 204 
G2: Freezing of gait 28 176 204 
G3: Postural stability 122 82 204 
G4: Dyskinesia 84 120 204 
 
2.4. Predictive Model Construction 
The self-evaluation metric provides an objective evaluation on motor related 
performance. However, this objective evaluation’s results are hardly useful for either 
patients or physicians, unless the self-evaluation metric can be associated with clinical 
assessment measurements. In order to build up this association, we attempted to construct 
a couple of predicative models to identify motor disabilities and estimate motor related 
UPDRS scores. To identify the four critical PD features, dyskinesia, gait difficulty, 
freezing of gait, and postural stability, we constructed four binary classification models 
using Support Vector Machine (SVM)(61). The ground truths of these four features are 
the UPDRS score rated from movement disorder experts at BNC’s movement disorder 
program. To train these classification models, we chose the all five items in the proposed 
self-evaluation metric plus patients’ age and disease duration to construct the input 
feature vector. The training process is done using the polynomial kernel in SVM(61) and 
10 folds cross validation(74).  All the 204 data records were equally divided into training 
set and test set. The 102 records were used to train the four classification models and the 
left 102 records were used in model validation and verification. 
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The midline motor activity score in UPDRS, ranging from 0 ~ 24, was estimated 
in a linear regression model. We used the same input feature vector, as well as training 
and testing procedure explained above. To avoid the collinearity between input features, 
the stepwise forward selection approach was applied in feature selection to build the 
linear regression model on midline motor score estimation (69). 
3. Result 
3.1. Patient general characteristics 
Table 4 presents the general patient characteristics of all 204 patients in this study. 
The average age is 68.3 years old, and average disease duration is 6.3 years. The average 
stage of Parkinson’s disease is 2.6 in term of Hoehn and Yahr stage, ranging from 0 to 5. 
The disease severity is measured using UPDRS. The average UPDRS motor score is 19.8, 
and the midline motor activity score is 5.6. Among the 204 patients, 41.2% (84) have 
dyskinesia, 13.7% (28) have freezing of gait, 36.3% (74) have gait difficulty, and 60.7% 
(124) have shown postural stability. 160 patients in this study were using levodopa in 
their disease management plan. 
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Table 4 
Patients general characteristics and UPDRS scores (N = 204) 
 Number Mean 
(SD) 
Range Median 
(Q1-3) 
Age (yr)  68.3(9.2) 40-89 69(62-75) 
Disease duration (yr)  6.3(4.7) 1-30 5(3-8) 
Using levodopa (number of Yes/No) 160/44    
Hoehn and Yahr stage  2.6(0.7) 0-4 2.5(2-3) 
UPDRS motor score  19.8(9.4) 1-55 18(14-25) 
UPDRS midline motor activity score  5.6(3.5) 0-16 5(3-8) 
Presence of motor related disabilities:     
         dyskinesia (Yes/No) 84/120    
         freezing of gait (Yes/No) 28/176    
         gait difficulty (Yes/No) 74/130    
         postural stability problem 
(Yes/No) 
124/80    
 
3.2. Validation 
This self-evaluation metric was validated by comparing the rating of each item of 
this metric between patient groups who have and do not have a specific motor related 
disability, listed in Table 3. The difference is compared in student T-test, at critical level 
of α=0.05. The null hypothesis H0 is that there is significant difference of self-evaluation 
rating between the patients with and without presence of a specific motor disability. The 
result is listed in Table 5. 
In Table 5, we can observe that in terms of balance difficulty, the self evaluation 
scores of standing on one leg, turning, tandem walking demonstrate significant increase 
of values from asymptomatic patients to symptomatic patients, and decrease of values of 
step length and step velocity. The same comparing differences exist in gait difficulty, 
freezing of gait, and postural stability. However, the differences on step length and step 
velocity between patients have or do not have dyskinesia are insignificant. The higher 
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scores of standing on one leg, turning, and tandem walking, meaning the poor 
performance in movement, the lower values of step length and walking velocity imply 
less motor ability. 
In gait difficulty comparison groups, ratings on standing on one leg, turning, and 
tandem walking show significant larger value in patients having gait difficulty than 
patients without the difficulty. The larger values in rating of standing on one leg, turning, 
and tandem walking indicate that the patient needs more help to finish the motor task, 
which suggests a more severe disease condition. The stride length and step velocity also 
show the consistent difference according to disease condition. For gait difficulty, the 
patients having gait difficulty exhibit shorter stride length and slower step velocity than 
the patients without the difficulty, and the differences are significant at p value < 0.05. 
Same as the comparison of gait difficulty, the similar comparison differences also exist in 
freezing of gait, postural difficulty, and dyskinesia. All these differences are significant at 
the p value < 0.05.  From t-test results, the self-evaluation metric shows a strong ability to 
differentiate the motor related performance of PD patients. The differences not only keep 
consistent with the condition of a disability, but also show strong significance in all the 
four types of motor disabilities. These comparison results serve as the validation evidence 
for the proposed self-evaluation metric to prove the consistency and reliability of using 
this metric in PD self-evaluation. After validation, the association between the self-
evaluation metric and motor disabilities was investigated by building the predicative 
models.  The performances and accuracy of the predicative models are discussed in the 
following session. 
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Table 5 
T-test result of each term in our proposed scale compared between patients whether 
having or not having balance difficulty, gait difficulty, freezing of gait, postural stability 
and dyskinesia. 
 gait difficulty freezing of gait 
No Yes p val
 
No Yes p-val
 
Stand on one leg 2.0±1.7 4.4±1.7 <0.0001 2.6±1.9 4.1±2.1 0.0021 
Turning 1.9±1.4 4.2±1.9 <0.0001 2.4±1.5 5.0±2.4 <0.0001 
Tandem walking 0.9±0.9 2.5±1.2 <0.0001 1.3±1.2 2.5±1.0 <0.0001 
Stride length 2.0±0.3 1.4±0.4 <0.0001 1.8±0.4 1.4±0.5 <0.0001 
Step velocity 3.6±0.8 2.4±0.8 <0.0001 3.2±0.9 2.5±1.0 0.0004 
 postural difficulty dyskinesia 
No Yes p val
 
No Yes p-val
 
Stand on one leg 1.8±1.8 3.5±1.9 <0.0001 2.3±1.9 3.6±1.9 <0.0001 
Turning 1.9±1.5 3.3±2.0 <0.0001 2.3±1.7 3.4±2.1 <0.0001 
Tandem walking 0.8±0.8 1.9±1.3 <0.0001 1.2±1.2 2.0±1.2 0.0002 
Stride length 2.0±0.3 1.6±0.4 0.0006 1.8±0.4 1.7±0.5 0.0047 
Step velocity 3.5±0.8 2.8±0.9 <0.0001 3.3±0.9 3.0±0.9 0.0184 
 
3.3. Predicative Model  
With the validated consistency and reliability of the metric, we further moved on 
to build the predicative models to identify critical motor disabilities and estimate disease 
severity. These predicative models play an important role in determining the competency 
and usability of this self-evaluation metric in home-based PD assessment and monitoring.  
3.3.1. Detect motor disability 
As described in Predictive models construction section, four classification models 
for identifying whether a patient has gait difficulty, postural stability, freezing of gait, and 
dyskinesia have been constructed using the Support Vector Machine (SVM) approach. 
Each model was trained and tested separately. The precision and recall are calculated for 
each model to show the accuracy of using the self-evaluation metric to identify whether a 
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patient suffering a motor disability, in Table 6. The classification model on gait difficulty 
identification shows the accuracy, 82.4% in recall, 82.7% in precision, and 82.3% in F 
measure. The accuracy of freezing of gait classification follows the gait difficulty. The 
recall, precision and F measure for freezing of gait are 76.5%, 74.9%, and 75.6% 
respectively. For postural stability and dyskinesia identification, the recall, precision, and 
F measure are all above seventy percent, and the classification models for these two 
disability identification show the similar accuracy.  
Table 6 
Recall, precision and F measure of the classification models for identifying gait difficulty, 
freezing of gait, postural stability and dyskinesia. 
 Gait difficulty freezing of gait postural 
stability 
dyskinesia 
Recall 82.4% 76.5% 71.6% 70.6% 
Precision 82.7% 74.9% 72.6% 72.1% 
F Measure 82.3% 75.6% 72.0% 69.9% 
ROC Area 0.906 0.728 0.724 0.75 
 
The ROC curves of these four models are compared in Figure 1. The ROC curve 
is a graphic plot usually used to illustrate the performance of a binary classification 
model. The ROC area, which is under the ROC curve, is for measuring the predictive 
ability of a classification model. The value of ROC area is from 0 to 1. Ideally, the 
perfect classification model has a ROC area of 1. Generally, the larger the ROC area is, 
the better performance of the classification model is. In Figure 1, the ROC area of 
classification model for gait difficulty, which is 0.906, is obviously larger than other three 
models. This large ROC area close to 1 indicates the strong ability of the model to 
identify the gait difficulty, using the self-evaluation metric. For freezing of gait, postural 
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stability, and dyskinesia, the ROC areas are 0.728, 0.724, and 0.75 respectively. In each 
of the four classification models, it can be observed that the recall and precision value of 
the model are very close, which suggests that the model has the same power in 
identifying a motor disability as excluding the possibility of disability. Because 
dyskinesia is most commonly related to the movement disability of upper body, 
especially hand, limp and face, it was assumed that this proposed metric may have very 
poor performance in identifying the upper body motor impairment, such as hand tremor 
and rigid face. However, the performance for classification dyskinesia shows acceptable 
accuracy, recall 70.6, precision 72.1, and ROC area 0.75. But for identifying the lower 
body related movement disability, especially for gait difficulty, our proposed metric 
indicates high accuracy. These four classification models will play the role in bridging 
the self-evaluation of patients with to the PD disease status, to identify several critical 
motor disabilities in home based PD assessment and monitoring. 
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Figure 1 
The ROC curve for classification models for PD related motor disabilities identification. 
 
3.3.2. Hoehn & Yahr stage estimation 
The Parkinson’s disease stage, Hoehn & Yahr score, is estimated using the 
patient’s self-evaluation information through regression model. The predicated variable, 
Hoehn & Yahr stage, ranges from 0 to 5. The predictor vector is composed of age, 
disease duration, standing on one foot, turning, tandem walking, stride length and 
walking velocity. By optimizing the model through the backward stepwise selection, the 
correlation coefficient of the final optimized regression model is r
 
= 0.85, and the root 
mean squared error is RMSE = 0.4.  
3.3.3. UPDRS score predication 
The classification models developed in this study provide an approach to detect 
critical motor related symptoms through the patient evaluation. However, in regular PD 
evaluation, the motor part of UPDRS score is a major indicator on severity of the disease. 
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In order to provide more quantitative information for physicians to capture the disease 
progress and severity of PD patients based on patients’ self-evaluation, we further 
attempted to predicate the UPDRS score using patients’ self rating. Since this proposed 
self-evaluation metric is for motor related evaluation, and more focus on assessing the 
motor ability of lower body, therefore, we chose the midline motor activity score in 
UPDRS to predicate. The midline motor activity score is calculated by summing the 
value of a subset of part III (motor examination) of UPDRS, including leg agility, arising 
from chair, posture, gait, postural stability, and body bradykinesia and hypokinesia(6, 58). 
Not like identifying the motor disability, which is binary result, the midline activity score 
is interval variable. To predicate this score, we applied the stepwise forward selection 
approach to construct a linear regression model(75). The input predicator vector started 
from containing only step length, which yields a model with correlation coefficient r = 
0.62 and root of mean squared error RMSE = 2.6.  By adding other independent variables 
to the predicator vector, the correlation coefficient was improved to r = 0.84 and RMSE = 
1.81. The final regression model is composed by five predicators, which include standing 
on one leg, turning, tandem walking and step length. Figure 2 shows the linear regression 
model on the test dataset (N = 102). The result of this regression model exhibits a strong 
correlation between the self-evaluation metric and the midline motor activity score. The 
regression model performs a good interpolation on the test dataset. Figure 3 shows the 
residue plot of the predicted value of midline motor activity score. The residue plot 
shows that 70.5% of the residues fall into the (-1, 1) region, and 95.1% of the residues 
fall into the (-2, 2) region. The R
2
 = 0.84 and residue plot figure demonstrate that this 
regression model has a favorable accuracy in estimating UPDRS midline activity score. 
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This model is promising to be implemented in home-based PD evaluation system to 
estimate the PD disease progress on axial motor performance evaluation.  
Figure 2 
The scatter plot on predicated vs. actual midline motor activity score of test data set, in 
the final regression model with correlated efficient r =0.84.  
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Figure 3 
Standardized residue plot of predicted UPDRS midline motor activity score. The red spot 
shows the outlier which has standardized error larger than 2. 
 
 
4. Discussion 
To explore a novel approach for home-based Parkinson’s disease, this initiative 
study proposed a simple Parkinson’s disease self-evaluation metric for PD patient self-
evaluation. The preliminary validation and analysis have been investigated. The analyses 
on the self-evaluation data of 204 participants in this study prove that the metric can 
effective evaluate the PD patient performance on motor related symptoms, and provide 
clinical meaningful information for disease status estimation. The validation result shows 
that this self-evaluation metric can effectively differentiate the different motor 
performance between patients having or not having specific motor disability. With the 
validated metric, four classification models and one linear regression model have been 
constructed to associate the patients’ self-evaluation rating with critical PD symptoms 
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and disease severity. The performances of these models were evaluated through the 
preliminary analyses. The results indicate acceptable accuracies of using this metric to 
identify critical PD motor disabilities, including gait difficulty, postural stability, freezing 
of gait, and dyskinesia. The estimation on midline motor activity score has also been 
investigated and the result shows a high correlated coefficient R
2
=0.84, which suggests a 
high accuracy to estimate axial motor performance.  
The validation on these metric and preliminary results of using this metric for 
basic disease status estimation show the usability of applying this metric in home-based 
PD assessment. This self-evaluation metric fills the gap between PD self evaluation scale 
and clinical used evaluation, so that the clinician can track the disease progress easily and 
more frequently through the patients’ self evaluation. However, the current version of this 
metric mainly focus on the evaluation on motor performance of lower body, and has 
limited power to assess the upper body performance, including hand tremor, face rigidity, 
and speech.  The other limitation is the subjective bias of the patients incurred in self-
evaluation, which can lower the effectiveness of using this self-evaluation metric in PD 
disease monitoring and management. Therefore, to resolve these limitations, we further 
explored other approach to provide more objective and efficient PD evaluation by using 
motion sensor technology and mobile information technology, which is discussed in 
CHAPTER 3 in this thesis.  
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CHAPTER 3 
SMARTPHONE BASED PD ASSESSMENT AND MONITORING APPROACH 
 
In CHAPTER 2, an initial attempt to design a home-based PD evaluation 
approach was discussed, and the results show acceptable accuracy and promising 
feasibility to implement this approach in PD management. However, using this self-
evaluation metric still requires patients’ subjective rating. Therefore, this approach is still 
subjects to perceptual bias and is less consistent and reliable. Moreover, the rating result 
of this self-evaluation approach contains only descriptive information about patients’ 
motor performance and but less quantitative motion feature information, which is 
important for more accurate PD assessment, predication of disease progress and cross 
patients’ comparison. At last, the limitation of this approach, which inhibits developing a 
system to monitor patients with PD, is that it is difficult to integrate the patients’ self-
reported rating, the analytical algorithms and data transmission  to estimate disease 
severity, to effectively monitor disease progress and to provide decision support in 
disease management. Moreover, there is no way to avoid manual input of the self-rating 
in real use case scenario, even when the analytics and data transmission framework is 
given. Therefore, these disadvantages largely limit the usability and clinical value of this 
approach and lower the feasibility of implementing this approach into a remote 
Parkinson’s disease monitoring system. To resolve these limitations, we further took 
advantage of the sensor technology, mobile computing technology and client/server 
architecture to develop a smart phone based e-health monitoring system on Parkinson’s 
disease management. The system design, development, and initial test and validation 
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were discussed in this chapter. This proposed system aims to provide an integrated home-
based PD assessment solution, which is convenient to use and reduce the subjective bias. 
1. Introduction 
Long-term clinical management of Parkinson’s disease requires extensive 
monitoring of a PD patient’s status and suitable medication plan according to the disease 
progress. The intermittent hospital assessment, which only provides a brief window to a 
person’s health, might miss trends that can lead to early detection of a problem(76). 
Home-based monitoring of PD is an ideal approach that has potential to fill the disease 
information gap of hospital monitoring, to reduce the necessity to attend frequent 
consultations with specialist personnel and to offer more precise and continuous 
monitoring paradigms to extensively assess PD progression and medication effects(77). 
With current and on-going advances in wearable sensor technology, wireless network and 
information platform, it becomes more feasible to monitor the physiological parameters 
remotely on a continuous basis in people’s daily activities. Such monitoring systems 
sensing PD related bio-parameters are promising tools that enable long-term PD 
monitoring at home basis.  
1.1. Home-based health monitoring system 
With the advance in sensor technology and the development of internet 
technology, the home-based monitoring system has drawn a lot of attention and efforts 
from both research and industrial communities to develop such kind of system to provide 
real-time health status information in managing chronic diseases and postoperative 
rehabilitation patients (78, 79). Several research prototype systems have been developed 
to monitor health status, using commercial products or custom hardware-based system. 
42 
The LiveNet, designed in the Media Laboratory of MIT, is a custom built system to 
monitor integrated physiological signal, including electrocardiogram (ECG), 
electromyogram (EMG) and blood pressure (BP, and posture position(80). AMON, an 
advanced care and alert portable telemedical monitor system, has been reported to 
provide real time measurement of blood pressure, skin temperature, blood oxygen 
saturation and basic ECG monitoring (81). Lin et al. described the development of a real-
time wireless physiological monitoring system (RTWPMS), which is based on a cordless 
phone and a custom made medical examination module to measure blood pressure, heart 
rate and temperature(82). Researchers in Harvard University have developed CodeBlue, a 
medical sensor network platform for multi-patient monitoring environment, using 
wearable wireless body area network (WWBAN)(83). As  multi-functionality and 
computing power of cell phone advances, attempts to use cell phone as data transmission 
and user interface control module have been reported in several health monitoring 
applications(84). HeartToGo is a cell phone based wearable platform, which is capable of 
continuously monitoring ECG signal via a wireless ECG sensor, to analyze the 
electrocardiogram in real time and possibly to detect any abnormal patterns pertaining to 
cardiovascular disease(85). These initial studies in health monitoring system have already 
the remote real time monitoring on vital signs, and many of them have been implemented 
in various use case scenarios, such as soldier health monitoring, space and terrestrial 
applications (80, 86). Due to the complicity of motoring features of PD and lack of 
automatic analytical and monitoring algorithm, there is few integrated monitoring system 
targeting on PD assessment. 
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1.2. Parkinson’s disease monitoring 
Given the characteristics of Parkinson’s disease and its challenges on disease 
management, designing ambulatory equipments for remote-monitoring PD patients has 
also attracted a lot of attentions recently, as can be observed in recent conferences(87-89) 
and study reports(90, 91). As tremor is one of the most significant motor disability 
symptoms of PD patients, several previous studies have reported prototype systems for 
tremor monitoring. Eskov et al described a research system for human micro movements 
that can be used to measure tremor using eddy-current detector(92). Hoff et al used a 
commercial portable multichannel recorder for quantitative continuous 24-hour 
monitoring of tremor while the patient is at home(93). Yang et al presented a portable 
device for long-term measurement and recording of tremor, using a compact flash 
memory card for storage(94). Besides tremor, gait is another critical PD feature that 
attracts a lot of research attentions to design ambulatory monitoring system and analytical 
algorithms. The primary measurement of gait mainly go into three avenues: i) force based 
measurement, ii) angular rate measurement and iii) accelerometer measurement(95). 
Several accelerometer based measurement systems for ambulatory monitoring gait 
related symptoms in PD have been reported in freezing of gait detection, posture and 
walking speed estimation (96-98). More recently, Salarian et al and Patel et al, in Harvard 
medical school, used wearable accelerometers to evaluate motor complications on 
persons with PD, and attempt to predicate the clinicians’ estimates of disease symptoms 
severity (99-101). Moreover, the ambulatory assessment on bradykinesia has also been 
investigated by using off-the-shelf accelerometer sensors by Cancela et al (88, 102). 
Except patients’ motor data, other information has also been studied for the use of PD 
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remote-monitoring. Little et al assessed the practical value of discriminating healthy 
people by detecting dysphonia(103). Tsanas et al proposed the use of speaking tests in the 
evaluation of PD progression(104). Goetz et al tested the feasibility of using a 
telemonitoring testing device in early-stage, unmedicated PD patients (105). 
1.3. Limitations and Challenges 
Despite recent advanced researches and studies in ambulatory monitoring of 
Parkinson’s disease and many attempts to develop a home-based monitoring system for 
PD management, most approaches are based on using separate sensor network and 
control module. By this way, the sensed data need to be transmitted to control and storage 
module through wireless network, and the system needs extra power supply for sensor 
and storage module and control module. These detached components increase complicity 
and decrease the system reliability (106, 107). Another big limitation of previous work on 
developing systems to monitor patients with Parkinson’s disease is the lack of integration 
between monitored data and analytical algorithms for providing integrated service for 
disease severity assessment and disease progress estimation. At last, such home-based 
disease monitoring system needs to be affordable and easy to be used by patients or care 
givers in the daily living environment, in order to ensure wide adoption and 
implementation in PD management. Therefore the current wearable sensor based 
monitoring system can hardly satisfy economic and usability requirements, due to 
hardware resource limitations and strict medical criteria. 
Portable electronic monitoring equipment has been used in assisting home 
monitoring of blood glucose, congestive heart failure, cardiovascular function and risk of 
falling down. Due to dramatic progress and rapid growth of smart phone applications, 
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especially the current tendency in mobile computing technology, more and more 
individuals have gained efficient access to information and communication solutions 
through smart phone platform(108). Current mainstream smart phone manufactories, 
such as Samsung, HTC and Apple, have already integrated the 3D accelerometer and 
gyroscope as a standard module to provide wide applications, such as orientation sensing 
and motion control. Since the major Parkinsonian symptoms are motor related disabilities, 
such as tremor, freezing of gait and walking difficulty, the accelerometer in smart phone 
may serve as a sensor component for motor exam in PD evaluation. With the high 
computing performance and powerful mobile operating system, data transmission, user 
interaction and storage can be seamlessly integrated to provide efficient PD monitoring. 
Moreover, with the ubiquitous 3G or wireless network, the smart phone can also serve as 
client terminal to communicate with the server-side analytics for disease monitoring and 
even medication consulting. An initial attempt to use iphone to assess tremor and gait 
difficulty of Parkinson’s disease patients were discussed in Lemoyne’s recent papers (109, 
110). The results showed it is promising to use the built-in 3D accelerometers to capture 
tremor and gait features of individuals with Parkinson’s disease. However, their study is 
very preliminary and did not discuss how to use the iphone sensed data to provide disease 
severity assessment and how to extend the iphone application to a monitoring system in 
PD management. In this chapter, we described a pilot PD home-based monitoring 
prototype system using smart phone device, web analytics and decision-supported 
technologies. The preliminary test of the system on PD patients was performed, and the 
test results will serve as feasibility evidence for future development or implementation. 
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2. Method 
2.1. System Design and Development 
2.1.1. System Architecture 
To provide ambulatory Parkinson’s disease monitoring and assessment through 
smart phone based mobile technology, this proposed system adopts three layers of 
architecture shown in Figure 4. These three layers are composed of: 1) the mobile unit, 
which is a smart phone with installed home-developed app to acquire patient’s motion 
data and to transmit data with server side; 2) the hospital server unit, which contains the 
analytics, and enables the medical staff remotely monitor the patient’s condition and send 
medical recommendations; 3) patient data warehouse, which is a patient centric relational 
database to store raw motion data and analysis results.  
In real use case scenario, patients use a specific app installed in the smart phone to 
log into the system and perform motor tasks for disease assessment. The real time motion 
data is sensed and acquired when patients performing a predefined motor task. After each 
motor task is done, the raw motion data and related test meta-data are stored on smart 
phone and then sent to hospital server unit when network is available. At the server’s side, 
received raw motion data are directly persisted into the patient data warehouse. While in 
a separate route, raw motion data goes through a series of pre-processing steps to remove 
noise and extract motion features and patterns. The extracted motion features are inputted 
into decision support modules for PD symptoms detection and disease severity estimation. 
Once some abnormal situations are observed or disease status declines, recommendation 
messages will be sent to physicians to require further review or follow up. Physicians can 
also send recommendation to patients through the system. Bidirectional transmission of 
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data between mobile unit and hospital server unit is implemented by the TCP/IP 
architecture using SOAP protocol. 
Figure 4 
System architecture diagram. 
 
2.1.2. Requirement Analysis 
In designing this system, function specification and requirement analysis were 
conducted before choosing test device. The requirements analysis to determine choosing 
which smart phone in this study was considered based on three factors: 1) device 
capability to effectively capture motion features related to Parkinson’s disease; 2) 
Communication and storage capacity; 3) Cost and device quality. The first factor is the 
major factor in determining which device was selected. 
The device capability for sensing and collecting motion features were analyzed 
based on the characteristics of PD motion data. In this study, hand resting tremor, 
walking, turning, and finger tapping data are four types motion data to be collected. It 
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was reported that hand tremor motion acceleration is along three directions, composed of 
low frequency components, less than 20 Hz, and the acceleration rate is less than 2g (111, 
112). Walking and turning acceleration signal is between 2 and 5 Hz(97). In order to 
extract gait features, including stride length, walking speed, and turning speed, both 
linear acceleration along x, y, z direction, and angular acceleration along pitch, yaw, and 
roll directions are required. Therefore, based on the above motion signal characteristics, 
the candidate device needs to have a 3D accelerometer and gyroscope sensors, and the 
3D accelerometer should have at least ±2g amplitude range.  
Furthermore, because the precision of collected motion acceleration signal is 
determined by sampling rate of sensor, the sampling rate is another factor that determines 
device selection. Based on the Nyquist-Shannon sampling theorem(113), the minimal 
sampling frequency should be at least 2 times of the highest frequency components. 
Therefore, the sampling rate of a qualified smart phone needs to support at least 40 Hz 
sampling rate, which is two times of the potential upper bound of hand tremor frequency 
component.  
In order to store collected motion data and related patient information, the 
selected smart phone should have at least 500MB storage space, and support basic 
database system and wireless or 3G internet communication. The cost of a candidate 
smart phone device should be in the middle class in current smart phone market and is 
mainstream brand. The over high end device will limit the future adoption of using this 
system, and over low end device will have high risk that influences the system stability 
and reliability. 
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2.1.3. Hardware 
Based on the above requirement analysis, we chose a Samsung Galaxy Epic smart 
phone, running on Android 2.1 Eclair operating system, as the mobile unit in this 
prototype system. We chose this device in this study considering the balance between 
required tech specs and economic cost. This device is mid-end product in smart phone 
market, and has standard tech specs and functional module compared with mainstream 
smart phones. Therefore, using this device is appropriate for test purpose to validate our 
system, and minimize variation of system performance resulting from device 
characteristics. Because this prototype system is developed for android system, so in real 
case implementation this proposed system can be extent to any android smart phones as 
long as they have built-in 3D accelerometer. This test device has 1GHz Gortex-A8 CPU 
and 512 MB internal memory, and can support Wi-Fi 802.11 b/g/n, Bluetooth, and USB 
2.0 data transmission protocol. The display of the device is 4.0 inches touch screen with 
resolution of 480 x 800 and supports multi-touch. The device is 124 × 65 × 14mm and its 
total weight is 155g. The power supply of the device is a standard Li-lon battery 
1500mAh, which can support stand-by time up to 300h and talk time up to 5h 30 min. 
The sensor module is composed of a tri-axial accelerometer, a proximity and a compass. 
Tri-axial accelerometer is capable of measuring up to +/- 8g and sampling frequency can 
be up to 1 KHz. This tri-axial accelerometer is used as the primary motion sensor module, 
which functions in the principle of differential capacitance in response to motion and 
constant gravity to measure both acceleration and inclination. 
The server side unit is a workstation constituted by an Intel Core 2 Duo 2.2 GHz 
computer with 4 GB of RAM, a hard disk of 250 GB and Microsoft Windows XP 
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operating system. The server is configured as a web server and data server, running 
Apache 5.5 and MySql 5.1. The workstation server is located in the restricted area and 
with password protection, and connected to the hospital network. In the prototype system, 
considering the limited volume of data load and scalability in test phase, we did not use a 
high performance workstation as dedicated server. In real implementation of the system, 
separated web server and data base server are highly desired. 
2.1.4. Software 
The software part in this system was developed in three parts: 1) smart phone 
application, using Android 2.1 SDK, 2) server side analytics running on Apache 5.5, and 
3) relational database MySQL 5.1. All these programs running on smart phone and on 
server were developed using Java programming language.  
2.1.3.1. Application on smart phone 
On the smart phone, we developed an application, named PD ODLs, for users to 
perform PD evaluation. The app was developed using the Android Software 
Development Kit (SDK), which provides the programming interface for sensor control, 
data storage and transmission. This SDK supports the custom setting on sampling rate of 
the accelerometer. We used the highest sampling rate supported by android platform in 
this study, which was tested up to 100Hz. On the smart phone side, an internal relational 
database, Sqlite, was also used in this system for temporary local data storage and user 
information management. In case neither wireless network nor cell phone network is 
available, acquired motion data can be temporarily stored in the internal database and 
then sent to server side when network is available. 
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Figure 5 
Graphical user interface of the application on smart phone. (A) User account log in and 
registration; (B) Motor test and data acquisition; (C) Communication module; (D) 
Review and manage test history.  
 
In order to make the application easier for patients to use, dedicated user-friendly 
user interface was developed. These interfaces are shown in Figure 5, and the workflow 
and information flow are shown in Figure 6. The software is composed of four main 
modules. The first module performs user account verification for data security and 
privacy protection (Figure 5A). The account authorization is required each time using the 
system. The second module acquires motion signals when patients completing motor 
tasks. Measurement of acceleration signals is collected simultaneously, at a sampling 
frequency of 100 Hz, when patients conducted the test. The sensed motion data are 
displayed on the smart phone screen when patient performing the task and are saved for 
further analysis. Totally four motor exams were designed for assessing different PD 
features (Figure 5B). After patient select one motor task, detailed instruction is displayed 
on screen to direct users how to perform task step by step. The third module is a 
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communication module based on SMS and email, which allows users to send questions 
and receive medical recommendations from the hospital server (Figure 5C). This could 
provide significant benefits for patients, allowing fast and easy adjustment of medical 
treatments. The fourth module enables users to review their test history and analysis 
result. This module also includes the function to send completed motor test data from 
smart phone to hospital server Figure 5(D). 
Figure 6 
State diagram of the application on smart phone for Parkinson’s disease evaluation 
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2.1.3.2. Hospital server side analytics 
On the hospital server side, all the analytical modules were developed under 
Spring Framework, using Service Oriented Programming (SOP) paradigm. Each module 
provides a single self-contained service, and all these modules are connected together 
using Spring Dependency Injection (DI). The framework of the server side modules is 
shown in Figure 7. The collected motor test data by smart phone are received in XML 
format at the server side. This XML file is first unmarshaled by the data preprocessing 
module to extract raw motion signal and test meta data, which includes sampling rate, 
time duration, date, type of motor test and user ID. The extracted data is then persisted to 
database, and also inputted into the signal processing module. In the signal processing 
module, the noise and Parkinson’s disease unrelated motion signal is filtered out, 
followed by calibrating signal to baseline. The filtered signal then goes into motion 
feature extraction module to extract PD related motion patterns and features according to 
each type of motor task. The motion features are categorized to two types: 1) time 
domain features and 2) frequency features. For different type of motor test, different 
motion features are extracted through specific analysis algorithm. The extracted features 
contain the input feature vector for the decision support module. The decision support 
module is composed of several individual predication models for detecting symptom and 
estimating disease progress. The output of the decision support module is estimated 
UPDRS (Unified Parkinson’s Disease Rating Scale) score for evaluating the disease 
status and tracking disease progress. 
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Figure 7 
Hospital server side architecture and data flow between analytics  
 
2.1.3.3. Data warehouse 
The back end patient relational database serves as the primary repository to store 
patients’ Parkinson’s disease motor test data and evaluation results. This database use 
patient-centric structure and use MySQL 5.1 as the database server. The raw motion data 
and estimated disease severity score of each disease assessment are persisted into this 
database. Figure 8 shows the ER diagram of the database structure. Beside the test data 
and disease assessment results, user account information is also managed in the database 
and all operations on database are logged using Apache log4j. One point that needs to be 
pointed out is that considering future potential needs to integrate this proposed system 
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with other research or clinical information system, this database structure reserves the 
interface for future extension. 
Figure 8 
ER diagram of the database system on hospital server side 
 
2.1.3.4. Data transmission 
The motion data collected by the motion sensors of smart phone is just a series of 
numeric numbers, which are not very meaningful for physicians and patients to 
understand. Therefore, the raw motion data must be processed and analyze through signal 
processing step to transfer to clinical meaningful information. In this data processing and 
analysis module, the input is raw motion data, and output is the estimated UPDRS scale 
(Unified Parkinson’s Disease Rating Scale). Because each PD related motion,  including 
hand tremor, gait and finger tapping, has different spectrum characteristics and distinct 
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motion pattern, so each type of PD related motion data goes through a specific designed 
data processing and analysis path respectively. The general path of data processing and 
analysis of motion data is shown in Figure 7, and explained in detail in the following 
three sections, data processing, feature extraction and disease severity estimation model. 
2.2. Parkinson’s disease motor assessment 
2.2.1. Motor tasks design 
In order to assess the major features of Parkinson’s disease through the smart 
phone, we designed four motor tasks to assess Parkinson’s disease severity in different 
dimensions. These four motor tasks are included in our designed monitoring system as 
regular routines to be performed in home-based PD evaluation. The rationale of the 
designing is based on our study result in CHAPTER 2 of this thesis. In CHAPTER 2, it 
has been found that the critical Parkinson’s lower body motor disabilities are associated 
with turning and walking performances. Many studies have proven that the finger tapping 
test is closely associated with bradykinesia, and using finger tapping test for 
quantification of bradykinesia has been attempted in many studies(114, 115). In addition, 
the hand resting tremor is a typical symptoms existing in most of the early stage PD 
patients(5). Therefore, we chose the turning, walking, hand resting tremor and finger 
tapping as the motor task set in this study. The detail descriptions for designed motor 
tasks are explained in Table 7, and the mount positions of the smart phone in hand resting 
tremor, walking and turning tasks are shown in Figure 9. 
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Table 7 
Designed motor tasks for Parkinson’s disease evaluation. 
Task  Task Description Data Description 
Hand Tremor 
Patient attaches the smart phone 
to the dorsum of each hand and 
keeps the hand hanging for 20 
seconds.  
Translational acceleration rate 
at X, Y, Z directions and 
angular acceleration rate at 
pitch, roll, and yaw directions. 
Walking 
Patient attaches the cell phone to 
the ankle of one leg and walking 
25 feet. 
Translational acceleration rate 
at X, Y, and Z directions and 
rotation matrix of cell phone 
with time change. 
Turning 
Patient attaches the cell phone to 
the pivot leg in turning 360
o
. 
Angular acceleration rate at 
pitch, roll, and yaw directions 
with time change. 
Finger tapping 
Patient tries to continuously tap 
the screen as soon as possible 
using index finger in 10s. 
The timestamp when patient 
tap the target. 
 
Figure 9 
Smart phone and motor test application in hand tremor task (A) and Walking & Turning 
task (B). 
 
2.2.2. Motion data analysis 
The collected motion signal goes through the signal processing and analysis steps 
before disease severity is estimated. Because in each motor task as described in Table 7, 
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motion signal has different characteristic and is featured with distinct patterns, so each 
type of motion signal goes through different signal processing path and is analyzed with 
specifically designed feature extraction algorithm. The following parts describe the 
processing flow and algorithm for each type of motion data. 
2.2.2.1. Hand resting tremor 
The raw acceleration signals along the three axes of the accelerometer were 
considered for the hand resting tremor analysis. Accelerometer signal consists of two 
different components, a acceleration component of motion and a gravity component 
related to the position of the accelerometer relative to gravity. In hand resting tremor, the 
change of hand position should not be considered as tremor related acceleration change. 
So a high pass filter (HPF) with 3-dB cut-off frequency at 0.3 Hz was first applied to 
removing gravity component of acceleration and slow displacement of hand. Because the 
hand tremor signals are at low frequency, usually 7~12 Hz for physiological tremor and 
4~6 for parkinsonian tremor, therefore a low pass filter with 3-dB cut-off frequency at 20 
Hz was then applied to remove the non-tremor related components. Fourier analysis was 
then applied on this filtered signal to calculate the frequency spectrum. Because a 
parkinsonian resting tremor has a typical frequency between 4 and 6 Hz but an action or 
postural tremor could also be present at higher frequencies (111, 116), so the 
characteristic of signal between 4~6 Hz and its ratio to other signal components were 
calculated to construct hand resting tremor feature set, shown in Table 8. 
  
59 
Table 8 
The extracted motion features of hand resting tremor evaluation. 
Tremor 
Features 
Description 
PF4_6 The power of the motion data between 4 and 6 Hz. 
%PF4_6 Fraction of power of motion data between 4 and 6 Hz. 
PR 
Power ratio of the motion data in 3.5 ~15 Hz to 0.15 ~ 3.5 Hz frequency 
components 
PF0_20 The total power of motion data from 0 ~ 20 Hz 
PEAK_P
OWER 
The peak power value of hand resting tremor motion data. 
AVG_A
CC 
The average acceleration of motion of hand resting tremor. 
 
The power of signal is calculated using equitation (1), where     is the signal in 
time domain. 
  
 
 
             
    
  
            (1) 
2.2.2.2. Gait 
The walking and turning task is for assessing the gait performance of individuals 
with Parkinson’s disease. From motion data collected in these two tasks, the primary aim 
is to extract the gait feature of the subjects to detect gait difficulty and freezing of gait. 
The extracted gait features are listed in Table 9. Gait is a periodic movement, which can 
be decomposed into a series of single gait cycles. Each gait cycle consists of stance and 
swing phase(117). Stance phase is approximately 60% of the gait cycle and begins at the 
end of the contact (EC) of foot on ground, goes through the loading phase, mid stance 
and ends at the initial contact (IC) of foot on ground. Therefore, to effectively extract the 
gait features, the major problem is to detect the swing and stance phase in each gait cycle, 
through detecting the IC and EC time stamp. After each IC and EC timestamps in gait 
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cycle are detected, the walking speed and stride length can be easily estimated by 
integrating the acceleration rate within the swing phase.  
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Table 9 
The extracted gait features from walking and turning motion data. 
Gait Features Description 
Walking Straight Task 
CT(s) Average gait cycle time. 
SL(m) Average stride length. 
SP(m/s) Average walking speed. 
AVG_ACC(m/s
2
) Average acceleration during walking. 
Turning Task 
NUM_TURN The number of step used to finish turning 360
o
 
TURN_SP The speed of turning 360
o
, calculated by 360
o 
/ time 
 
To detect the gait cycle and extract gait features from the acceleration signal 
collected by the smart phone, the acceleration along the ,  and   direction were used in 
gait analysis, as shown in  
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Figure 10. The acceleration waveform of gait cycle was shown in Figure 11. 
Normally, acceleration signal of a single cycle gait shows characteristic peaks. In the  -
axis, there is a smooth positive peak in swing phase and a sharp positive peak next to EC. 
In the  -axis, there are a smooth positive peak in swing phase and some positive peaks 
near EC event. However, abnormal gait sometimes shows peaks with different 
characteristics. Due to slow movement of Parkinson’s disease patients, the positive peak 
during the IC–loading phase in the  -axis is usually weak when distinguishing the IC 
peak from the next positive peak. In the  -axis, the amplitude during swing phase is 
similar to the amplitude of other peaks; therefore, it is difficult to exactly discern the 
swing phase.  
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Figure 10 
The attaching position of the smart phone in walking task. The  ,   and   are three axes 
of sensors and equivalent to horizontal, vertical and transverse direction respectively. 
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Figure 11 
Acceleration waveform of gait cycle. The dotted lines are marked ECs, ICs, swing (SW) 
phase, and stance (ST) phase. 
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Figure 12. Diagram to show algorithm for extracting gait features. 
 
 
According to the characteristics of gait, the anterior–posterior acceleration (ax) 
and proximal–distal acceleration (ay) signals were processed sequentially to find the EC 
and IC peaks. The lateral acceleration (az) was highly dependent upon the individual, and 
therefore, was only used for non-walking period removal. The algorithm consists of 
seven steps as illustrated in Figure 12. Each step is described below in detail. 
 Step 1: Bias removal 
The original acceleration signal at three directions, ax, ay and az contains the 
gravitational acceleration, which is changed with slow transition movement. To 
remove the gravitational component, a second order low pass Butterworth filter (LPF) 
with 3-db cut-off frequency at 0.5 Hz was applied to the original acceleration signals 
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to extract gravitational component(118). By subtracting the gravitational component 
from the original signal, the bias-removed signals               were obtained. 
 Step 2: Non-walking period removal 
In order to assess the dynamics of activities, magnitude of the ankle’s 
acceleration (                   ) was calculated. Periods of dynamic activity 
were searched using a simple threshold method just as Veltink et al. used(119). At 
first,     was filtered with the 0.1 Hz low pass filter, LPF   . If a point in the 
filtered signal was above 1/10 of the value of gravity, that point was assigned to a 
dynamic point, Figure 13(a). In this study, we considered an isolated gait as a non-
walking period. Therefore, when dynamic samples were connected for > 2 s, those 
periods were grouped into candidates of walking periods. Other periods were grouped 
as non-walking periods. 
 Step 3: Stance and swing phase discrimination:  
During candidates of walking periods, stance phases were detected. A stance 
phase is the phase when foot is in total contact with the ground. At this phase, the 
dynamics of activity is at the lowest point in the walking cycle. In order to determine 
the stance phase,     was compared with a threshold value LPF   , where LPF    
was obtained from 0.1 Hz low pass filtered ||a||. The gait signal at vertical 
direction   , was divided into sub-segments by 0.1 seconds. If more than two 
consecutive sub-segments had lower value than LPF   , those were determined as 
stance phase. The other subsegments were determined as swing phase. The time 
stamp at beginning of a swing phase was extracted as end of contact (EC) time, and 
the time at end of a swing phase was extracted as initial of contact (IC) time. 
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Figure 13 
Comparison between    and LPF    for a non-walking period removal. 
 
 
 Step 4: Peak detection: 
Simple peak detection method was used in the detected swing phase(120). 
Among many detected peaks, peaks shown in vertical and horizontal acceleration 
signal simultaneously were selected.  
 Step5: Removal of non-gait peak:  
In the selected peaks, if the amplitude of a peak is lower than threshold value, 
which is set to 1/5 of LPF   , or the shapes of   and   accelerations near a peak are 
different, those peaks are removed. In the remained peaks, if the interval of two 
consecutive peaks is less than 0.5 second, one of two peaks is removed selectively. At 
last, the remained peaks not removed by the above rules are determined to be the gait 
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peaks. The positive peaks and negative peaks are saved in each swing phase. The first 
positive peak in each swing phase is the acceleration of initial of a step (ACC_INI) 
and the last negative peak is the end of a step (ACC_END). 
After these five steps were completed, the EC, IC, positive peaks and negative 
peaks were detected per swing phase. With these detected features, the following two 
steps were applied on               to estimate stride length and walking speed. 
 Step7: Walking speed estimation:  
With the detected swing phase in each gait cycle, walking speed is calculated. 
Walking speed is contributed by two directions of acceleration,    and    in world 
coordinate system, Figure 14(b). The     direction is tangential to the ground at the 
device’s current location and roughly points east, and    is tangential to the ground at 
the device’s current location and point’s towards the magnetic north pole. To 
compute the displacements along    and   axes, we first applied a low pass 
Butterworth filter with 2.5 cutoff frequency to               to remove noise and 
walking unrelated signal. This filtered signal is denoted as             s. Because 
the acceleration signal              is measured by accelerometer in reference 
coordinate system of cell phone, shown in Figure 14(a), and because the position of 
cell phone changes with body movement, thus the coordinate system of cell phone is 
not constant and cannot be used as reference coordinate system for measuring either 
displacement or velocity. As the real world coordinate system is usually seemed as a 
constant system, the estimation of velocity and displacement needs to use real world 
coordinate as reference. Therefore, the acceleration signals measured in cell phone 
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coordinate system need to be transformed to real world coordinate system first. The 
acceleration signal in cell phone system,    
     
     
  , is transformed into signal real 
word coordinate system     
     
     
   by: 
    
     
     
      
   
   
   
  
Where R is the rotation matrix, which is a 3 x 3 matrix saved with acceleration 
signal together in data collection by android system. 
With transformed acceleration signal in real world coordinate system, we 
computed the associated velocities      and     , 
          
       
 
 
      
          
       
 
 
      
Where      and      are the initial horizontal and vertical velocity at the 
beginning of a swing phase, and   is the time offset from the beginning of a swing 
phase. The      and      were combined together for final walking speed in a swing 
phase                     . 
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Figure 14 
Coordinate system of smart phone (a) and real world system (b) 
                           
          (a)                                                                         (b) 
 
 Step8: Stride length estimation:  
After obtaining the velocities      and     , horizontal displacement       
and vertical displacement,      , were obtained by integration, 
               
 
 
      
               
 
 
      
Where      , and        are the initial horizontal and vertical positions before 
the start of a swing phase. The continuous walking motion was segmented into a 
series of swing phase. In each swing phase, initial conditions for integration were 
assumed to be        ,        ,        , and        . The final stride 
‘ 
‘ 
‘ 
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length was calculated by                     , where t is the duration of each 
swing phase.  
The extracted swing phase duration, speed, stride length, acceleration at initial 
and end of a step were averaged of all swing phases to get the averaged value listed in 
Table 8. 
In turning task, the sensed acceleration data at y direction    was used to identify 
each turning step. The 1
st
 to 4
th
 steps of the algorithm shown in Figure 12 were applied to 
   to detect the number of steps, NUM_TURN were detected for completing turning 360 
degree, and the average turning speed TURN_SP divided the 360 degree to get time used. 
2.2.2.3. Finger tapping 
In finger tapping test, individuals in tests were requested to use their index finger 
to tap a target appearing on the center of smart phone screen. The timestamp of each 
attempt tapping the target was saved and marked with whether success or failure of 
hitting the target. The number of tapping (NUM_TAP) within 10 seconds, the average 
interval (INTVL_TAP) between two taps and the tapping frequency (FREQ_TAP) were 
calculated as finger tapping features, shown in Table 10. 
Table 10 
The extracted features from finger tapping test. 
Finger tapping 
Features 
Description 
NUM_TAP The number of tapping on screen in 10 seconds. 
FREQ_TAP The average finger tapping frequency. 
INTVL_TAP The average interval between two attempts to tap the screen. 
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2.2.3. Decision support 
The decision support module provides critical symptom detection and disease 
severity estimation in this system. Here we utilized a subset of data mining techniques 
that are suitable for assessing whether different disease status are marked by specific 
patterns or disease progress trends from the extracted motion features. We used 
supervised learning method Support Vector Machine (SVM) to detect critical symptoms, 
including bradykinesia, fall, gait difficulty, freezing of gait, postural stability, and hand 
tremor, and use regression model to estimate the Parkinson’s disease stage in term of 
Hoehn & Yahr score and motor disabilities severity on UPDRS scale. All constructed 
decision support models for PD assessment in this study are listed in Table 11. 
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Table 11 
Decision support models in smart-phone based PD monitoring and evaluation system. 
The predictors (features), predicated value, and type of model are listed per model. (The 
descriptions of referenced predictors are listed in Table 8, Table 9, and Table 10) 
Model 
ID 
Predictors Predicated Value 
Predicated Value 
Type 
Classification models: 
SVM_1 Age, Disease duration, CT, SL, 
SP, AVG_ACC, NUM_TURN, 
TURN_SP, NUM_TAP, 
TAP_FREQ, INTVL_TAP 
Bradykinesia Binary classification 
SVM_2 Age, Disease duration, CT, SL, 
SP, ACC_AVG, NUM_TURN, 
TURN_SP 
Fall Binary classification 
SVM_3 same as SVM_2 Gait difficulty Binary classification 
SVM_4 same as SVM_2 Freezing of gait Binary classification 
SVM_5 same as SVM_2 Postural stability Binary classification 
SVM_6 Age, Disease duration, 
NUM_TAP, LAG, INTVL_TAP, 
PF4_6, %PF4_6, PR, PF0_20, 
PEAK_POWER, AVG_ACC 
Hand tremor Binary classification 
Regression models: 
REG_1 Age, Disease duration, CT, SL, 
SP, AVG_ACC, NUM_TURN, 
TURN_SP, NUM_TAP, 
FREQ_TAP, INTVL_TAP, 
PF4_6, %PF4_6, PR, PF0_20, 
PEAK_POWER, AVG_ACC 
Hoehn&Yahr 
Stage 
Numeric: 0, 1, 1.5, 
2, 2.5, 3, 4, 5. 
REG_2 same as SVM_6  UPDRS: Tremor 
at rest 
Numeric: 0, 1, 2, 3, 
4 
REG_3 same as SVM_3 UPDRS: Gait 
difficulty 
Numeric: 0, 1, 2, 3, 
4 
REG_4 same as SVM_5 UPDRS: Posture 
stability 
Numeric: 0, 1, 2, 3, 
4 
 
2.2.3.1. Predictive variable selection 
As described in 2.2.2 Motion data analysis section, specific motion features were 
extracted from the designed motion tasks in this study. These motion features were used 
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as predictors in constructing predictive models for PD symptom detection and disease 
severity detection. Because each PD symptom impairs different aspects of patients’ motor 
ability, we selected different motion features to compose base predictor set for each 
predictive model specifically. With a base predictor set, an original regression model was 
constructed and then stepwise backward selection steps were applied to reduce the 
dimension of predictors. 
In hand resting tremor detection, the predictors were chosen from the motion 
features extracted from hand resting tremor task. Based on the frequency characteristics 
of hand resting tremor motion signal, the acceleration signal between 4~6 Hz range is an 
important indicator of hand resting tremor (111, 116). Several studies have reported using 
power spectrum analysis for detecting hand resting tremor, and discussed the feature 
selection results(121). Based on these existing results and heuristic selection, the power 
of motion data between 4 ~ 6 Hz (PF4_6), fraction of power of motion data between 4 ~ 
6 Hz (%PF4_6), power ratio of the motion data in 3.5~ 15Hz to 0.15 ~ 3.5 Hz frequency 
components (PR), total power of motion data from 0 ~ 20 Hz( PF0_20), the peak power 
value of hand resting tremor acceleration (PEAK_POWER), and average acceleration of 
hand resting tremor (AVG_ACC) were selected as the base predictor set for hand resting 
tremor predictive models. Besides these selected features, patient age and disease 
duration were added into the predictor set, considering the association of these two 
factors with PD progress. 
In detecting and estimating lower body motor disabilities, including fall, gait 
difficulty, freezing of gait and postural stability, we composed the base predictor set from 
walking and turning tasks. In the result of PART 2, the step length, walking speed, and 
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the number of steps used for completing turning 360 degrees, have shown strong 
association with balance difficulty, freezing of gait (FOG), gait difficulty, and postural 
stability. Therefore, the average gait cycle time (CT), average stride length (SL), average 
working speed (SP), average acceleration during walking (AVG_ACC), number of step 
used to finish turning 360
o
(NUM_TURN), and turning speed (TURN_SP) were selected 
to compose the base predictor set for lower body disability assessment.  
One study using finger tapping test for detecting bradykinesia reported strong 
association between the speed of finger tapping and bradykinesia(115). Therefore, for 
bradykinesia detection, the speed of finger tapping was measured using the number of 
tapping in 10 seconds (NUM_TAP), average finger tapping frequency (FREQ_TAP), and 
average interval between two taps (INTVL_TAP). These three variables were chosen as 
base predictor set for bradykinesia detection.  
In stepwise backward feature reduction step, the F test criteria at significance 
level at α = 0.1 was used. We eliminated the predictor with the lowest F value for the test 
of significance of the predictor, conditioned on the F-value being smaller than the criteria 
value, F0. The criteria F0 value was pre-defined at significance level of α = 0.1, which is 
F0 = 3.14. Next, we fitted the reduced model (having removed the predictor from the 
original model), and remove from the reduced model the predictor with the lowest F-
value for the test of significance of that predictor. And so on. The backward stepwise 
selection procedure ends when no more predictor can be removed from the model at 
significance level α = 0.1.  
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2.2.3.2. Support Vector Machine (SVM) classification 
SVM is a type of supervised machine learning technique that can automatically 
adjust its capacity according to the scale of a specific problem by maximizing the width 
of classification margin(122, 123). One of the benefits is its ability to explore more 
information from the given data by using a nonlinear function to map the original features 
into a high-dimensional space as shown in the following description.  
Let the training set D be             
 , with each input    as one motion feature, 
and the output label as      . With the nonlinear function Φ, input vector x is mapped 
to Φ(x). The optimal classifier is obtained by solving a quadratic optimization problem: 
  α   α 
 
   
 
 
 
                
 
     
       
With                 , in which C is the regularization parameter that 
controls the trade-off between model complexity and error. According to the Kuhn–
Tucker theorem, samples that have      must lie along with the margins of the decision 
boundary, which are called support vectors, To avoid computation of the inner product 
             in a high-dimensional space, only those functions that can satisfy Mercer’s 
condition,                       , are considered to be the kernel. With the derived 
support vectors, the decision function for a new sample x is expressed as 
                      
        
       
  
In SVM, the kernel function plays as an important role in determining the final 
classification accuracy. Typical kernel functions include linear, polynomial and radial 
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basis function (RBF). Previous studies have reported the performance of different kernel 
functions in detection on motor disabilities. Kamruzzaman et al. compared different 
kernel functions for the diagnosis of cerebral palsy gait and reported that RBF and 
polynomial kernel function obtained good overall accuracy (124, 125). In Patel et al.’s 
study, it was reported that the polynomial kernel has a better performance than RBF 
kernel in bradykinesia classification (100). Since there are no analytical results about 
which kernel function is optimal in Parkinson’s disease status classification, we tested 
both polynomial and RBF kernel to determine the final SVM model. 
The polynomial kernel is used for creating nonlinear classifier to maximum-
margin hyperplanes. This kernel function allows the classifier to fit the maximum-margin 
hyperplane in a transformed hyperplane in the high-dimensional feature space. The 
polynomial kernel function is: 
                
  
Where d is the degree of the kernel function, which is determined by testing the 
performance of the SVM model through bootstrapping d at different value [2, 3, 4, 5]. 
The kernel function of RBF is: 
              
       
 
   
  
Where   controls the width of the radius in RBF kernel and needs to be 
determined in training SVM model. In this study, the width of radius is optimized by 
grid-search and cross-validation procedures. The parameters are firstly digitized through 
a number of grids, and for each grid, performance of the SVM classifier is evaluated by 
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the 10 fold cross-validation(74). The optimal values can be found by exhaustively 
searching in all of the parametric grids.  
2.2.3.3. Regression 
To estimate general PD disease stage and each specific motor disability severity, 
the regression analysis approach was applied to predicate Hoehn & Yahr scale, and 
UPDRS motor scores, including tremor at rest, posture, gait, postural stability and 
bradykinesia. Considering the limited number of training data and the redundancy of 
motion feature, the Lasso regression was applied to eliminate the irrelevant or redundant 
predictors and diminish the effect of over-fitting(126). Lasso regression is a regularized 
version of least square approach for estimating regression model, by adding a 
regularization constraint into the loss function. The loss function of Lasso regression is 
defined as: 
             
 
 
 
 
     
 
 
 
 
 
Where     denotes the  th predictor (feature) in the  th record,   denotes the 
value of the response in  th data record, and  
 
 denotes the regression coefficient of the 
pth predicator. The norm-1 regularizer    
 
 
 
  in Lasso regression typically leads to a 
sparse solution in the feature space, which means that the regression coefficients for most 
irrelevant or redundant features are shrunk to zero. The   controls the model complexity. 
The regression coefficients are estimated by minimizing the value of loss function: 
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2.3. Recruiting and Data Collection 
To test this smart phone based Parkinson’s disease evaluation and monitoring 
system, an evaluation study on this system was tested in clinical setting at Muhammad 
Ali Parkinson Center (MAPC) at St Joseph’s Hospital and medical center (SJHMC). This 
evaluation study has been approved by IRB at St Joseph’s Hospital and Medical Center 
(IRB#:12BN033) and Arizona State University’s IRB (IRB#:1208008142). The collected 
data were analyzed to investigate using motion data for Parkinson’s disease evaluation, 
and validated the accuracy of using this system to detect critical Parkinson’s symptoms 
and to estimate disease severity. 
 Recruiting 
We recruited 40 out-patients, who have been diagnosed having Parkinson’s 
disease and have shown motor related symptoms, from the Muhammad Ali Parkinson 
Center (MAPC) at St Joseph’s Hospital and medical center (SJHMC). No pregnant 
women, children under 18 years of age, mentally incompetent individuals, and 
individuals with conditions that increase their vulnerability, were recruited. Patients who 
receive UPDRS (Unified Parkinson’s Disease Rating Scale) based evaluations as part of 
their regular clinic visits were invited to participate in this study. The study instructions 
and consent forms were given to patients and explained by the principal Investigator. If 
patients agree to participate in this study, they signed the consent forms, which were 
collected by the principal investigator. The participation is voluntary, and patients can 
withdraw from participation at any time during the study. 
 Data Collection 
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Data collection was conducted at MAPC during patients’ regular clinical visit. 
Only one SAMSUNG Galaxy Epic smart phone was used in this study. To protect the 
privacy and identification of participants, once the patient agrees to participate in this 
study, a study ID was assigned to this patient for identification purpose. The study ID is a 
unique numeric number, and doesn’t include any information that could be potentially 
related to Protected Health Information, such as DOB, medical record ID, or SSN.  This 
study ID is the only identification information that was stored with collected data, and 
was used to differentiate the data related to different patients. After the consent forms 
were collected, the test procedure was explained to participant during their regular visits. 
The principal investigator directed and assisted the participants to complete the full set of 
3 tests. 
 Hand resting tremor test: the principal investigator will assist patient to 
wear a wrist band on one hand, and attach the test device to the wrist band. Then the 
patient will keep one hand hanging for 20 seconds for data collecting. After the 
recording of one hand is done, the wrist band is taken off. Repeat the same procedure 
on the other hand. 
 Gait difficulty test: physician will assist patient to attach the test device on 
one of their ankle using an ankle band. Then the patient will be asked to walk straight 
25 feet, and then turn 360 degrees. The motion data during the patient’s walking and 
turning will be recorded. After the recording of one leg is done, the ankle band is 
removed. Repeat the same procedure on the other leg. 
 Finger tapping test: the patient in the finger tapping test will be asked to 
use the index finger to hit the target alternative appearing on the across corner of cell 
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phone screen as fast as possible in 15 seconds. Then switch to the other hand to repeat 
the same procedure. 
All these three tests together take approximately 5 minutes for each participant to 
complete. After test procedure was completed, participant’s disease status was evaluated 
using UPDRS (Unified Parkinson’s Rating Scale) scale. The collected motion data and 
UPDRS scores rated by physician were analyzed to validate the accuracy and provide 
feasibility evidence of this smart-phone based approach.  
3. Results 
To evaluate the performance of this smart-phone based PD monitoring and 
evaluation tool in detecting critical PD symptoms and to estimate motor disability 
severity, 40 subjects were recruited for the clinical laboratory-based tests. The 
recruitment and data collection procedure followed the protocol described in Recruiting 
and Data Collection section. The motion features of PD patients at different disease 
severity stages were extracted and compared first, and the accuracy of the predicative 
models for PD symptom detection and motor disability severity estimation were analyzed 
and discussed in this section.  
3.1. General patient description 
Table 12 shows the general characteristics of all 40 participants recruited in this 
study. Among these 40 patients, 5 were female and 35 were male. Ages of the 
participants ranged from 44 to 84, and the average age was 68.5 years old. The disease 
duration distributes from 0 to 19 years, and the median disease duration was 6 years and 
average disease duration was 6.6 years. Among all subjects, 16 of them were in early 
disease stage (disease duration less than 6 years), and 24 subjects were in late disease 
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stage (disease duration more than 6 years).  The average Hoehn & Yahr stage was 2.4. 
There were six subjects at stage 1, 13 subjects at stage 2, 12 subjects at 3, and three 
subjects at stage 4. No subjects at the stage 5 were recruited in this study. The severities 
of motor disabilities were evaluated by two movement disorder experts using UPDRS 
scale. If their evaluations differ, the third rater was invited. The detail scores for each 
UPDRS item, rated by experts, were shown in Table 12. In these 40 subjects, 10 of them 
had bradykinesia, 9 subjects had freezing of gait, 11 subjects had gait difficulty, 15 
subjects had postural stability problems, and 5 subjects reported having falls on weekly 
basis. Because most of the recruited patients were from follow up clinic visits, not new 
diagnosed patients, therefore most of them, 32 subjects, were using levodopa when they 
participated in this study.  
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Table 12 
Patients general characteristics and UPDRS scores (N = 40) 
 Mean (SD) Range Median (Q1-3) 
Age (yr) 68.5±9.5 44-84 70(63-74) 
Disease duration (yr) 6.6±4.0 0-19 6(4-8) 
Hoehn & Yahr stage 2.4±0.8 1-4 2(2-3) 
UPDRS arising from chair score 0.5±0.8 0-3 0(0-1) 
UPDRS posture score 1.0±1.1 0-4 1(0-2) 
UPDRS hand resting tremor score 1.7±0.7 0-4 1(0-3) 
UPDRS gait score 1.1±1.0 0-4 1(0-2) 
UPDRS freezing of gait score 0.4±0.9 0-4 0(0-0) 
UPDRS postural stability score 1.2±0.9 0-3 1(0-2) 
UPDRS bradykinesia score 1.5±0.8 0-3 0(0-3) 
UPDRS finger tapping score 1.0±0.8 0-3 0(0-2) 
UPDRS dyskinesia score 1.7±0.6 0-4 1(0-4) 
Presence of motor related disabilities: Number   
     bradykinesia (Yes/No) 10/30   
     freezing of gait (Yes/No) 9/31   
     gait difficulty (Yes/No) 11/29   
     postural stability problem (Yes/No) 19/21   
     falls (Yes/No) 5/35   
 
3.2. Hand resting tremor analysis 
As described in the system design and motor task design sections, the 
accelerometer signal of hand resting tremor is recorded through 3D accelerometer of the 
smart phone testing device. The signal profiles of the acceleration rate of hand resting 
tremor were analyzed to find the association between motion features of hand tremor 
motion and severity of Parkinson’s hand resting tremor. Amplitude of the fluctuation may 
vary with the change of severity of the tremor. The sample acceleration waveforms 
collected from participants whose UPDRS hand resting tremor scores were from 1 to 3 
were shown in Figure 15. In Figure 15, the right hand column pictures show the 
comparison of acceleration waveforms of hand resting tremor from patients with different 
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UPDRS hand resting tremor scores. The pictures in right column are power spectrum 
density (PSD) plots according to the left acceleration waveform. The magnitude of PSD 
of hand motion acceleration demonstrated obvious difference between patients whose 
UPDRS hand resting tremor score were from 1 to 3. In the sample patients UPDRS hand 
resting tremor score = 1, shown in Figure 15 (A) right hand, the acceleration of hand 
motion was around 1 m/s
2
. The corresponding power spectrum mainly dominated around 
5 Hz, and the peak power was up to 20 (m/s
2
)
2
. When hand resting tremor was severe, the 
acceleration rate of hand motion and the power spectrum density both exhibited 
substantial increasing tendency. As observed in Figure 15 (B), when the severity of hand 
resting tremor went up to 2, the average acceleration of hand motion was about two times 
greater than those patients whose hand resting tremor UPDRS score = 1 in Figure 15 (A). 
The power spectrum also displayed larger value, around 40 (m/s
2
)
2
, and the peak power 
appeared at higher frequency at around 7 Hz, which showed in Figure 15 (B). From hand 
resting showed in Figure 15 (B) that tremor UPDRS score increase from 2 to 3, the peak 
power spectrum increased from 40 (m/s
2
)
2
 to around 60 (m/s
2
)
2
, and continuous large 
acceleration of hand tremor, mainly range from 3 ~ 5 m/s, was observed in Figure 15 (C). 
Therefore, from demonstration of the acceleration signal profile in hand resting tremor 
test, collected motion signal could capture the difference between hand motion data of 
PD patients who were at different severity stage of hand resting tremor. There is one 
point that needs to be pointed out. In previous studies about characteristic of Parkinson’s 
hand resting tremor, it was reported that the hand resting tremor mainly predominate 
between 4 ~ 6 Hz (111). In this study, our collected hand resting tremor data 
demonstrated the same characteristic. As demonstrated in right hand column pictures of 
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Figure 15, the hand resting tremor also mainly predominated between 4 ~ 6 Hz. This 
evidence also validated our method with the previous experimental result. Therefore, 
these acceleration waveform analysis and power spectrum anal results indicate that our 
smart phone based approach can effectively capture motion features of hand resting 
tremor and differentiate the motion patterns among different severities. 
Figure 15 
Acceleration waveform and power spectrum density (PSD) plot of hand resting tremor at 
different severity level. A) Hand resting tremor UPDRS score = 1; B) Hand resting 
tremor UPDRS score = 2; (C) Hand resting tremor UPDRS score = 3. 
 
(A) 
 
(B) 
 
(C) 
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Statistics of extracted motion features from hand resting tremor test were shown 
in Table 13, in which the difference of motion features were compared between patients 
whose UPDRS hand resting tremor score < 2 and patients whose UPDRS hand resting 
tremor score ≥ 2. The average acceleration of those whose UPDRS hand resting tremor 
score < 2 was 0.6±0.2 m/s
2
, and 1.7±0.4 m/s
2
 for those UPDRS hand resting tremor score 
≥ 2. In spectrum analysis, frequency response showed that the hand resting tremor was 
predominated in the frequency range between 4~6 Hz. The total power of hand resting 
tremor signal between 0 ~ 20 Hz was 100.7 (m/s
2
)
2
 for patients whose UPDRS tremor 
score < 2, and 259.4 (m/s
2
)
2 for those whose UPDRS tremor score ≥ 2. The peak power 
was 53.7±13.2 for patients whose UPDRS tremor score < 2, and 75.2±16.6 for patients 
whose UPDRS tremor score ≥ 2. These comparison results indicated that motion features 
of hand resting tremor represent significant difference between different severities of 
hand resting tremor. For those patients suffer severe hand tremor (UPDRS tremor score 
≥2), the power of acceleration was between 4~6 Hz (PF4_6), and total power (PF0_20), 
power ratio (PR), peak power (PEAK_POWER), and average acceleration (AVG_ACC) 
were significant greater than those with mild hand tremor (UPDRS tremor score < 2).  
Table 13 
Extracted motion features from hand resting tremor test, results were divided into two 
groups, UPDRS hand resting tremor <2, and UPDRS hand resting tremor ≥ 2. (The 
meaning of each motion feature is described in Table 8)  
Hand resting tremor 
motion features 
UPDRS tremor 
score < 2 
UPDRS tremor 
score ≥ 2 
P-value 
Significanc
e 
(α=0.05) 
PF4_6 6.1±2.1 14.4±5.2 0.04 * 
%PF4_6 0.07±0.01 0.06±0.02 0.54  
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PR 0.79±0.4 1.1±0.35 0.09 * 
PF0_20 100.7±25.9 259.4±56.0 0.014 * 
PEAK_POWER 53.7±13.2 75.2±16.6 0.039 * 
AVG_ACC 0.6±0.2 1.7±0.4 0.006 * 
 
3.3. Gait analysis 
In the course of Parkinson’s disease development, motor disabilities in lower 
body play substantial effects on impairing walking, balance, postural stability, and even 
induce to falling. To effectively assess the status of PD in home based monitoring, the PD 
patients’ motor performance in lower body was investigated through measuring gait 
performance. To measure gait performance, the accelerations in three directions were 
collected during patients’ walking and turning. Gait features in turning and walking, as 
listed in Table 9, were extracted by using the gait signal processing analytics, which were 
discussed in CHATPER 3, section 2.2.2. In order to give an intuitively introduction about 
acceleration changes during walking, acceleration waveforms of sample patients with 
different gait difficulty severities were first shown in Figure 16. Then the extracted gait 
features were compared between patients whose UPDRS gait difficulty score < 2 and 
those whose ≥ 2 in student T test.  
The sample acceleration waveforms of patients during working were shown in 
Figure 16. In Figure 16, the demonstrated gait waveforms were captured from four 
typical patients with UPDRS gait difficulty score at 0, 1, 2, and 3 respectively. Black dot 
line on each figure marked each gait cycle, based on automatically analysis result from 
designed analytics. Figure 16 (A) showed the gait acceleration waveform of PD patients 
who had UPDRS gait score = 0. The gait profile exhibited consistent repeating pattern, 
and the swing and stance phrase showed clear boundaries. The peak acceleration during 
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each gait also illustrated consistent value, and the positive peak instant acceleration was 
up to 8 m/s
2
, while the negative peak instant acceleration was up to 12 m/s
2
. When gait 
difficulty was worse, the gait pattern and acceleration values exhibited obvious difference 
among acceleration waveforms. In Figure 16 (B), which is from a PD patient with 
UPDRS gait difficulty score at 1, gait pattern showed different traits. A consistent gait 
cycle was still observed in this patient and the boundaries between each gait cycle were 
still clear. But the peak accelerations during walking were much lower - below 5 m/s
2
. 
For a patient whose gait difficulty was evaluated at 3, shown in Figure 16 (C), the gait 
cycle became blurry and the acceleration profile showed inconsistent and unstable pattern. 
The peak acceleration during walking was primarily around 2 m/s
2
, however in some 
steps the peak acceleration can suddenly climbed to 10 m/s
2
. Figure 16 (D) showed the 
data from a patient with gait difficulty score at 3, coming along with freezing of gait 
(FOG). It can be seen that this patient’s gait cycle was discontinuous, and there was a 
long gap from 3.6s to 5.3s, and from 6.2s to 8.2 s, during which strong resistance to 
moving appeared.  
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Figure 16 
Acceleration waveforms in walking. A) UPDRS gait score = 0; B) UPDRS gait score = 1; 
(C) UPDRS gait score = 2; (D) UPDRS gait score = 3. 
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(D) 
Based on the intuitive illustration of acceleration waveforms and discussions, 
quantitative features of gait were extracted. As described in Table 9, the listed motion 
features during walking and turning were extracted from walking and turning from all 40 
patients. These motion features were compared between patients who do not have gait 
difficulty (UPDRS gait difficulty score < 2) and who have gait difficulty (UPDRS gait 
difficulty score ≥ 2). The comparison results were shown in Table 14. The average gait 
cycle time (CT) of patients not having gait difficulty was 1.1±0.32s, smaller than the 
average gait cycle time at 1.22±0.49s from patients having gait difficulty. The stride 
length (SL) and walking speed (SP) showed significant greater value on patients not 
having gait difficulty than patients having gait difficulty. The average stride length (SL) 
of patients without gait difficulty was 1.26±0.17m and was1.07±0.29m for patients with 
gait difficulty. The average walking speed of patients without gait difficulty was faster 
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than the patients with gait difficulty, 1.15±0.20m/s vs. 0.87±0.28m/s. The average 
acceleration value during walking straight was 5.2±1.1m/s
2
 for patients without gait 
difficulty, while 3.6±1.7m/s
2
 for patients with gait difficulty. Except the walking cycle 
time (CT), all other three walking features SL, SP, and AVG_ACC were significant 
different between patients having gait difficulty and not having gait difficulty.  
On turning task, the number of steps completing a whole round and turning speed 
was calculated from the collected motion data. For patients without gait difficulty, the 
average steps for completing a whole round was 3.1±0.9 steps, and the average turning 
speed was 79.1±8.49 degree/s. As expected, for patients with gait difficulty, 5.4±1.1 steps 
were needed to complete a whole round and the average turning speed was 53.7±6.98 
degree/s. The difference of numbers of turning steps and turning speed were significant 
between patients with and without gait difficulty.  
Table 14 
Extracted motion features from walking and turning test, the results are divided into two 
groups, UPDRS gait score <2, and UPDRS gait score ≥ 2. (The meaning of each motion 
feature is described in Table 9) 
Gait Features 
UPDRS gait score 
< 2 
UPDRS gait score 
≥ 2 
P-value 
Significance 
(α=0.05) 
Walking straight     
CT(s) 1.1±0.32 1.22±0.49 0.076  
SL(m) 1.26±0.17 1.07±0.29 0.035 * 
SP(m/s) 1.15±0.20 0.87±0.28 0.026 * 
AVG_ACC(m/s
2
) 5.2±1.1 3.6±1.7 0.038 * 
Turning 360
o 
    
NUM_TURN 3.1±0.9 5.4±1.1 0.042 * 
TURN_SP(degree/s) 79.1±8.49 53.7±6.98 0.039 * 
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3.4. Finger tapping analysis 
In finger tapping test, the participants were required to use their index figure to 
continuously tap a target on smart phone screen as soon as possible for 10 seconds.  
Timestamp of each tapping was recorded by the smart phone. From the recorded 
timestamp, the numbers of tapping screen was counted, and the average interval and 
frequency of tapping were derived. Because finger tapping test is a typical clinical 
measurement for bradykinesia, the calculated statistics were compared between patients 
who have bradykinesia and those who do not, shown in Figure 17. Patients who do not 
have bradykinesia have averagely 25.4±2.8 times tapping in 10 seconds, while patients 
who do have bradykinesia have 16.7±3.3 times. The average interval between two 
tapings was 0.4±0.08s for patients without bradykinesia and 0.67±0.11s for patients with 
bradykinesia. This result suggests that finger tapping speed can be significantly affected 
by bradykinesia, which potentially decreases the agility finger as well as the speed of 
finger movement. 
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Figure 17 
Average interval and frequency of finger tapping in finger tapping test, compared 
between patients who have bradykinesia and those who do not have bradykinesia. 
 
 
3.5. Predicative models evaluation 
As discussed in 3.2~3.4, the motion features extracted from hand resting tremor, 
waling, turning and finger tapping, show potential to capture the difference between 
different severities of PD symptoms. In this section, these motion features were further 
used to construct predicative models to rate disease stages, to detect critical parkinsonian 
symptoms, and even to estimate the severity of some motor disabilities. Using the 
methods described in 2.2.3 in this chapter, estimations to Hoehn&Yahr stage, hand 
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resting tremor, gait difficulty, bradykinesia, postural stability and freezing of gait were 
attempted in this study. 
3.5.1. Disease stage estimation 
In clinical practice, the Hoehn&Yahr (H&Y) stage is widely used for assessing 
the stage of Parkinson’s disease. In home based PD evaluation, the estimation of 
Hoehn&Yahr stage is an indicator of current disease status for PD patients. Therefore, 
predicative model to estimate H&Y stage was first constructed using Lasso 
regression(126). Regression results are shown in Figure 18. The correlation coefficient of 
the regression model for H&Y estimation was r = 0.81, the averaged absolute error was 
0.26, and the root mean squared error was 0.34. The scatter plot of this regression model, 
in Figure 18(A), exhibited a strong correlation between predicated H&Y stage and actual 
H&Y stage. The box plot, in Figure 18(B), showed the range of estimated stage and error 
of each H&Y stage. For patients at actual H&Y stage 1, 1.5, 2, 2.5, 3, and 4, the average 
estimated H&Y stage were 1.30±0.3, 1.65±0.15, 2.01±0.19, 2.43±0.21, 2.99±0.16 and 
3.7±0.12 respectively. This regression model showed strong correlation between 
extracted motion features and H&Y stage, and the accuracy of the estimation results was 
sufficient for estimating Parkinson’s disease stage in this smart phone based approach. 
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Figure 18 
Result of regression model to estimate the H&Y stage. (A)The scatter plot on predicated 
vs. actual H&Y motor stage, with correlated efficient R
2
=0.81. (B) The box plot to show 
the range of estimated H&Y stage with average error, grouped in each H&Y stage. 
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(B) 
3.5.2. Detecting Motor disabilities  
For Parkinson’s disease, the hand tremor, gait difficulty, bradykinesia, and 
postural stability are critical symptoms. With the progress of disease and decline of motor 
performance, the motor disabilities can future induce to freezing of gait and fall, which 
could greatly impair living quality of PD patients. In this designed system, the above 
critical symptoms of PD plus freezing of gait and fall were detected using the extracted 
motion features from acceleration captured by smart phone. Six classification models 
were constructed to detect whether an individual suffers hand resting tremor, gait 
difficulty, postural stability, freezing of gait, bradykinesia, freezing of gait or predicating 
falls. These classification models were trained using Support Vector Machine (SVM) 
approach (61, 124). The precision and recall of each model were calculated to evaluate 
the accuracy and to provide the bench mark for validation of this smart phone based PD 
evaluation approach. 
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The evaluation results of these six models are shown in Table 15. For hand resting 
tremor detection, recall and precision were 0.77 and 0.82 respectively. The accuracy of 
bradykinesia detection was at the same level as hand resting tremor, with the recall of 
0.77 and precision of 0.83.  On detecting lower body motor disabilities, especially the 
walking associated disabilities, the results showed higher accuracies, which were above 
80% in both recall and precision value. High accuracy in detecting the walking related 
disabilities might result from that features extracted in walking and turning tasks are 
highly correlated to walking related disabilities. As listed in Table 15, in gait difficulty, 
freezing of gait and postural stability detection, the recall were 0.89, 0.87 and 0.84 
respectively, and accordingly the precision value were 0.81, 0.87 and 0.90. For fall 
detection, the recall was 0.75, and the precision was 0.76. The F measure combines 
precision and recall in evaluating the overall performance of the classification model. In 
all these six models, the models with lowest F measure, 0.77, were for bradykinesia and 
fall detection. F measure of models for gait difficulty, freezing of gait, and postural 
stability detection were all above 0.85, which means the very high accuracy to detect the 
existence of the symptoms. Overall, these classification results indicated high accuracy 
for detecting some key Parkinson’s disease related motor disabilities from using the 
motion data collected from our smart phone based system. The analytics for processing 
and analyzing motion data were also proved expected functionality and promising future 
in home based PD assessment and monitoring. Using the smart phone application and the 
functionality of analytics, physicians can find appearance of patients’ new symptoms at 
earlier time, and patients can also have better understanding of their current disease status 
and progress tendency.   
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Table 15 
Classification results of detecting motor disabilities 
 Hand 
resting 
tremor 
Bradykinesia 
Gait 
difficulty 
Freezing 
of Gait 
Postural 
Stability 
Fall 
Recall 0.77 0.73 0.89 0.87 0.84 0.75 
Precision 0.82 0.83 0.81 0.87 0.90 0.76 
F Measure 0.79 0.77 0.85 0.87 0.86 0.77 
ROC Area 0.74 0.78 0.85 0.84 0.87 0.76 
 
3.5.3. Estimating UPDRS score of motor disabilities  
Section 3.5.2 discussed the results of using our smart phone based system to 
detect substantial motor disability symptoms. However, these functionalities are based on 
binary classification, which can only indicate whether a patient has or not have a 
symptom. It can hardly tell how severe one symptom is. In current Parkinson’s disease 
assessment, UPDRS measurement is a widely accepted standard for assessing severity of 
parkinsonian symptoms. In order to make this smart phone system more compatible with 
UPDRS measurement, motion features captured by the smart phone are required to be 
converted in order to predicate UPDRS scores. Otherwise, information captured by this 
system is less meaningful for physicians and patients to really obtain the disease severity 
and further track the disease progress. In order to bridge this conversion, UPDRS hand 
resting tremor score, gait difficulty score, postural stability score and bradykinesia score 
have been estimated using Lasso regression. The accuracy and the estimation error of 
each regression model were discussed in this section. 
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Figure 19 
The result of regression model to estimate UPDRS hand resting tremor score. (A)The 
scatter plot on predicated vs. actual hand resting tremor score. (B) The box plot to show 
the range of estimated score and the estimation error. 
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(B) 
 
Results of estimation of hand resting tremor score are shown in Figure 19. The 
correlation coefficient of the regression model on hand resting tremor score estimation 
was r = 0.74, and the averaged absolute error was 0.55. The box plot showing the 
estimation range and error of estimated tremor score in Figure 19 (B) displayed that the 
average estimation on patients with actual hand resting tremor score of 0 were 0.27 ± 
0.21, the average estimation for patients with actual hand resting tremor score of 1 were 
0.93 ± 0.17, the average estimation for patients with actual hand resting tremor score of 2 
were 2.01 ± 0.15, and the average estimation score were 2.94 for patients whose actual 
hand resting tremor score were 3 ± 0.24. Because the UPDRS scores are integer value, by 
rounding the estimated hand resting tremor score by regression model, the severity of 
hand resting tremor can be estimated effectively. 
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Figure 20 
The result of regression model to estimate UPDRS gait score. (A)The scatter plot of 
estimated vs. actual gait score. (B) The box plot to show the range of estimated gait score 
and the average estimation error. 
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 (B) 
 
Figure 20 showed the results of estimation on UPDRS gait score using our 
constructed regression model. The correlation coefficient of regression model for gait 
score estimation was r = 0.79, which suggests a strong correlation between extracted 
motion features and the UPDRS gait difficulty score. The average absolute estimation 
error was 0.46. Since the UPDRS scores are all integer value, most of the estimation error 
can be eliminated by rounding the output of the regression model. The box plot, Figure 
20 (B), demonstrated the output range regression model for groups of patients with 
UPDRS gait difficulty score of 0, 1, 2 and 3. The average estimation on gait difficulty 
score was 0.24 ± 0.11 for patients with actual gait difficulty score of 0, 0.89 ± 0.28 for 
patients with actual gait difficulty score of 1, 1.83 ± 0.25 for patients with actual gait 
difficulty score of 2, and 2.93 ± 0.22 for patients with actual gait difficulty score of 3. 
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Figure 21 
The result of regression model in estimating UPDRS postural stability score. (A)The 
scatter plot showing the predicated vs. actual postural stability score. (B) The box plot to 
show the range of estimated postural stability score and the average estimation error. 
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(B) 
Figure 21 showed the results of regression model in estimating UPDRS postural 
stability score. The correlation coefficient of regression model for postural stability score 
estimation was r = 0.76, and the average absolute error was 0.38. The box plot, in Figure 
21 (B), illustrated that the average value of estimated gait score were 0.34 ± 0.15, 1.06 ± 
0.24, 2.05 ± 0.20, and 2.99 ± 0.23 for patient groups with actual postural stability score of 
0, 1, 2, and 3 respectively.  
In this section, estimation of UPDRS scores on hand resting tremor, gait difficulty 
and postural stability were investigated and the results suggested that using motion 
features captured by our smart phone system are feasible to be used to estimate severities 
of some parkinsonian motor disabilities’. Correlation coefficient from 0.6 ~ 0.8 suggests 
strong association. In this study, all these regression models showed strong associations 
between motor disabilities of Parkinson’s disease and motion features captured using our 
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designed smart phone system. These strong associations and accuracy results indicated 
possibility and feasibility of using this smart phone system to provide clinical meaningful 
information in Parkinson’s disease home based monitoring. 
4. Discussion 
It is expected that home based disease monitoring will be increasingly applied in 
the coming years with widely implementation of healthcare information technologies(82). 
Monitoring and evaluation of Parkinson’s disease at home could reduce costs, enable 
follow-up of disease status change after specific medical treatments, and facilitate 
longitudinal research study by tracking disease progress. In this context, we developed a 
home based evaluation and monitoring system for Parkinson’s disease assessment. This 
system takes advantage of the current smart phone as the platform to provide integrated 
functions including data collection, storage, analysis and information transmission. To 
achieve this purpose, we developed the patient end application on smart phone, server 
end analytics, and tested this system on Parkinson’s patients through evaluating the 
accuracy of this system. 
While the home monitoring enables longitudinal disease monitoring and home 
based evaluation, it also places stringent constraints on the system: cost, size, 
unobtrusiveness, ease of use and maintenance of signal quality. The system developed in 
this study work is simple to use, safe and does not require extra setting and equipments. 
The only equipment required is a smart phone with built-in 3D accelerometer. During 
disease evaluation, patients only need to briefly interrupt their daily activities, bind the 
smart phone to their hands and ankles while completing some simple walking, turning 
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and finger tapping activities. The system has a user-friendly interface that records display 
collected motion signals and supports wireless communication with server side. 
In the experimental validation, we collected motion data from 40 parkinsonian 
subjects, analyzed these motion data and compared it with clinical experts’ evaluation on 
the patients’ disease status to study the correlation between using motion features. The 
validation results indicated that this smart phone based system can effectively capture the 
important motion features from acceleration signals to differentiate PD severity and 
identify critical symptoms. The predicative models constructed in this study to estimate 
disease severity indicated high accuracy and promising future. The motion features 
extracted from motion acceleration signals are more objective and quantitative than 
subjective rating performed by physicians in PD assessment. The accurate rates to detect 
hand resting tremor, bradykinesia, gait difficulty, freezing of gait, postural stability and 
fall were 79%, 77%, 85%, 87%, 86%, and 76% respectively. All these accuracies are 
between 70~90%, which indicate moderate diagnostic accuracy. The correlation 
coefficient for estimating of Parkinson’s disease stage is r = 0.81, 0.74 for hand resting 
tremor, 0.79 for gait difficulty and 0.76 for postural stability. The correlation coefficient 
results indicated strong association between the motion features extracted from 
acceleration signals and the severity of symptoms. The number of experimental subjects, 
40 in this study, to some extends, limits the accuracy of symptoms diagnostic and disease 
severity estimation. In future study, with the increase of available data, these predictive 
models will be refined to achieve higher accuracy.  
One limitation of the study is that the proposed system for home based PD 
monitoring only has limited in clinical validation, and lacks home setting validation. The 
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present work was more dedicated to describe a new design and development of a novel 
system, and to provide preliminary patient tests data to show that the system is useful in 
motor disability measurement and to prove the future feasibility of using this system in 
remote home based PD evaluation and monitoring. It is not a demonstration that this 
system will be clinically successful in monitoring Parkinson’s patients. This would 
require broader and more sufficient clinical studies, which requires more dedicated 
patient tests on both clinical setting and home setting. Because of limitation of funding, 
patient resources and the restrict requirement of FDA approval, the clinical validation 
aim is beyond the scope of this study. 
Moreover, another limitation of this study is the lack of sufficient validation on 
the effect of intra-individual variation on assessing severity of Parkinson’s disease by 
using smart phone. Because the pattern of motion features might differ from patient to 
patient even though they are at the same severity level, using general decision support 
models for assessing PD severity on all patients is more bias induced. Furthermore, it is 
possible that for same PD patient, the motion features may also represent different 
signature at different situations, such as environmental or physiological changes. These 
variations can affect the accuracy of assessment, and reduce the usefulness of this system 
for home-based PD monitoring. To reduce the influence of intra-individual variation on 
PD assessment, more sophisticate design of experiment will be needed in future to 
validate analytical algorithms and decision support models. One validation approach is to 
group similar patients into one experimental group based on demographic and disease 
characteristics. In each group, the motion data will be analyzed and compared with rated 
UPDRS scores. The predicative models and analytical algorithm will be built specifically 
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for each patient group. By this way, this group based validation can provide more 
sufficient and extensive information to prove the usefulness of smart phone based 
evaluation in home-based PD assessment and monitoring. The other validation needed in 
future is to test a same patient in a period of time and sample multiple motion data, in 
order to collect and test the change of collected motion data with the change of patient 
living situation or other physiological situation change. However, these two validations 
rely on recruiting more patients and requiring enough funding support. With current 
limitations in funding and time frame, these validations have not been accomplished in 
current stage of this study, and are proposed in next stage of this study. 
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